

## Scientific Program

### BIOCHEMISTRY/MOLECULAR ONCOLOGY

Room A, 09:00-11:00  
Thursday, October 8

Chair Persons: J. Lennartsson, A.M. Zubiaga, M.R. Sanderson

163. Mechanism of platelet-derived growth factor (PDGF) Erk5 MAP-kinase activation is cell type-dependent and can be independent of PDGF receptor kinase activity. M. Tsioumpekou, N. Papadopoulos, F. Burovic, C.-H. Heldin, **J. Lennartsson** (Uppsala, Sweden) (30')
267. Oncogenic and anti-oncogenic roles of E2F transcription factors. A. Iglesias-Ara, J. Mitxelena, A. Apraiz, J. Vallejo, G. Mentxaka, A. Fullaondo, **A.M. Zubiaga** (Bilbao, Spain) (30')
318. Drug targeting of Type II topoisomerases across species. I. Laponogov, X.-S. Pan, D.A. Veselkov, T. Umrekar, I.M.-T. Crevel, J. Selvarajah, D. Magrioti, L.M. Fisher, **M.R. Sanderson** (London, UK) (30')
199. 3' end mRNA tagging: A novel quality control mechanism that coordinates mRNA translation and degradation. **I. Morozov**, M.X. Caddick (Coventry; Liverpool, UK) (30')

### qPCR TECHNIQUES AND APPLICATIONS

Room A, 11:30-13:30  
Thursday, October 8

Chair Persons: M.W. Pfaffl, M. Kubista

314. MIQE challenges and solutions: The use of -omics technologies for transcriptional biomarker discovery. **M.W. Pfaffl** (München, Germany) (40')
372. Expression profiling of circulating tumor cells. **M. Kubista**, R. Sjöback, M. Jindrichova, E. Rohlova, V. Rusnakova, K. Kolostova, S. Hauch, B. Aktas, M. Tewes, M. Bredemeier, S. Kasimir-Bauer (Göteborg, Sweden; Prague, Czech Republic; Langenhagen; Essen, Germany) (40')
295. The use and usefulness of amplification curve analysis in quantitative PCR. **J.M. Ruijter**, M.J.B van den Hoff, A. Ruiz-Villalba (Amsterdam, The Netherlands) (40')

## CANCER THERAPEUTICS

Room A, 15:30-17:30  
Thursday, October 8

Chair Persons: E. Agostinelli, I. Mus-Veteau

203. Polyamine metabolites induce cytotoxicity on tumor cells: New approaches in cancer therapy by nanocarriers. **E. Agostinelli**, C. Barrero, S. Ohkubo, S. Grancara, M.V. Russo, S. Merali, A. Toninello (Rome; Padua, Italy; Philadelphia, PA, USA) (30')
124. The Hedgehog receptor Patched: A new target for cancer treatment, first inhibitors of the multidrug resistance activity of Patched. L. Fiorini, M.A. Tribalat, L. Sauvard, J. Cazareth, E. Lalli, I. Broutin, O.P. Thomas, **I. Mus-Veteau** (Valbonne; Nice; Paris; Marseille, France) (30')
142. Generation of oxidative stress as an anticancer therapeutic strategy. T. He, E. Hatem, L. Vernis, **M.-E. Huang** (Orsay, France) (30')
477. BRCA mutation and personalized treatment in pancreatic cancer. **G. Luo**, K. Jin, Z. Liu, C. Liu, X. Yu (Shanghai, P.R. China) (30')

## microRNAs

Room A, 18:00-20:00  
Thursday, October 8

Chair Persons: I. Groisman, J.R. Boyne

161. The WEE1 regulators CPEB and miR-15b switch from inhibitors to activators at G2/M. G. Kratassiouk, L.L. Pritchard, S. Cuvellier, A. Vislovukh, Q. Meng, R. Groisman, C. Degerny, E. Deforz, A. Harel-Bellan, **I. Groisman** (Gif-sur-Yvette; Paris, France; Kiev, Ukraine; Harbin, P.R. China) (30')
284. Next-generation sequencing reveals novel cellular targets for Merkel cell polyomavirus miRNA. P. Ahkbari, **J.R. Boyne** (Bradford, UK) (30')
265. Expression of monocyte chemoattractant protein-1-induced protein 1 in neuroblastoma modulates transcriptome including microRNAs. **H. Rokita**, E. Boratyn, I. Nowak, I. Horwacik, M. Durbas, J. Jura (Kraków, Poland) (30')
309. Role of microRNAs in B-cell development and lymphoma. **G. Malpeli**, S. Barbi, G. Tosadori, G. Scardoni, A. Scarpa (Verona, Italy) (30')

IMMUNOLOGY/MOLECULAR ONCOLOGY

Room B, 09:00-11:00  
Thursday, October 8

Chair Persons: T. Grundström, Z. Granot

256. Mechanisms controlling diversification and affinity maturation of antibodies. **T. Grundström**, J. Hauser, C. Grundström, R. Kumar, T. Ahmed (Umeå, Sweden) (30')
338. Dynamic changes in neutrophil composition dictate overall contribution to cancer. J.Y. Sagiv, J. Michaeli, S. Assi, I. Mishalian, H. Kisos, L. Levy, P. Damti, D. Lumbroso, L. Polyansky, R.V. Sionov, A. Ariel, A.-H. Hovav, E. Henke, Z.G. Fridlender, **Z. Granot** (Jerusalem; Haifa, Israel; Würzburg, Germany) (30')
375. Sirtuin-1 controls Th17 differentiation and Th17-dependent tumor growth by its capacity to deacetylate Stat3. **E. Limagne**, R. Euvrard, M. Thibaudin, P. Chalons, F. Végran, H. Berger, L. Apetoh, F. Ghiringhelli, D. Delmas (Dijon, France) (25')
241. Genome instability in brain disorders: Linking inherited and non-heritable mutations to genetic-environmental interactions. **I.Y. Iourov**, S.G. Vorsanova, Y.B. Yurov (Moscow, Russia) (20')
544. Targeting human kallikrein 2, hK2, with 11B6 antibodies for radionuclide imaging and therapy of prostate cancer. **T.A. Tran**, O.V. Timmermand, S.-E. Strand (Lund, Sweden) (15')

CLINICAL ONCOLOGY/MOLECULAR ONCOLOGY

Room B, 11:30-13:30  
Thursday, October 8

Chair Persons: E. Healy, B. Köberle

238. Cutaneous squamous cell carcinoma: A changing of the guard. C. Lai, J. Theaker, A. Al Shamkhani, **E. Healy** (Southampton, UK) (30')
258. Platinum(IV)nitroxyl complexes as a new family of potential chemotherapeutic drugs. **B. Köberle**, M. Cetriz, S. Schoch, J. Rauch, V. Sen, A. Hartwig (Karlsruhe, Germany; Moscow, Russia) (30')
257. Inhibition of receptor tyrosine kinase signaling in leiomyosarcoma cells using the small molecule Vatalanib®. **A. Gaumann** (Bavaria, Germany) (25')
382. Patient selection for peptide receptor radionuclide therapy. **I. Karfis**, P. Flamen (Brussels, Belgium) (20')
546. Triterpene-loaded microemulsion using *Coix lacryma-jobi* seed oil for enhanced antitumor efficacy: Preparation, characterization and *in vivo* evaluation. **Y. Chen**, D. Qu, J. He, C. Liu, J. Zhou (Nanjing, P.R. China) (15')

## METASTASIS/PROGRESSION

Room B, 15:30-17:30  
Thursday, October 8

Chair Persons: P. Coopman, L.-G. Yu

415. Role of the Syk tyrosine kinase in the intercellular adhesion and invasion of breast cancer cells. T. Kassouf, P. Montcourrier, R. Larive, N. Bettache, F. Mérezègue, A. Morel, S. Urbach, **P. Coopman** (Montpellier, France) (25')
101. Peanut consumption on cancer metastasis: A likely risk factor in cancer survival. **L.-G. Yu** (Liverpool, UK) (25')
528. Role of the tumour suppressor PML in prostate cancer progression. M.E. Buczek, A.K. Miles, W. Green, C. Johnson, D.J. Boocock, A.G. Pockley, R.C. Rees, G. Hulman, G. van Schalkwyk, R. Parkinson, J. Hulman, D.G. Powe, **T. Regad** (Nottingham; Derby, UK) (25')
416. The role of voltage-gated sodium channels in cancer and metastasis. **H. Gumushan-Aktas** (Sanliurfa, Turkey) (25')
144. Fucosylation in cancer stem cells from oral squamous cell carcinomas: Implication for invasion and metastasis. **V. Desiderio**, P. Papagerakis, V. Tirino, L. Zheng, M. Matossian, A. De Rosa, F. Paino, L. Mele, R. Montella, M.E.P. Prince, G. Papaccio, S. Papagerakis (Ann Arbor, MI, USA; Naples, Italy) (20')

## APOPTOSIS/HYPOXIA

Room B, 18:00-20:00  
Thursday, October 8

Chair Persons: Y. Suzuki-Karasaki, H.M. Said

207. Depolarization mediates pro-apoptotic mitochondrial network abnormalities in cancer cells: A possible mechanism of tumor targeting. **Y. Suzuki-Karasaki** (Tokyo, Japan) (30')
411. Carbonic anhydrase 9 modulation by the regulative effect of hypoxic oxygenation and cytokine expression in human hepatocellular carcinoma - *in vitro*. **H.M. Said**, R. Safari, Y. Soysal, D. Harmancı, C. Hagemann, J. Anacker, M. Flentje, F. Kockar (Izmir; Balıkesir, Turkey; Würzburg, Germany) (30')
232. p62 participates in the inhibition of NF- $\kappa$ B signaling and apoptosis induced by sulfasalazine in human glioma U251 cells. **J. Su**, Y. Wu, L. Shen, Y. Xue, X. Yan, L. Sun (Changchun, P.R. China) (20')
456. The interaction between TRAIL and IER3 mediates apoptosis in hepatocellular carcinoma through the downregulation of the Wnt/ $\beta$ -catenin/WISP1 signaling pathway. **S. Liu**, H. Pan, R. Yao, Y. Liang, X. Liu, L. Wang, Z. Liu, Z. Chen, S. Sun, J. Liang (Shandong; Fujian; Beijing, P.R. China) (20')
308. Antitumor cellular systems with induced apoptosis. **E. Milkina**, I. Bryukhovetskiy, A. Naborschikov, P. Mischenko, Y. Khotimchenko (Vladivostok, Russia) (20')

## EXPERIMENTAL CARCINOGENESIS

Room C, 09:00-11:00  
Thursday, October 8

Chair Persons: W. Liu, T. Eckschlager

105. TERT polymorphism and EGFR mutations in NSCLC: A linkage between somatic changes and germline variation. **W. Liu** (West Lafayette, IN, USA) (30')
386. Nanocarriers with encapsulated doxorubicin and their effect on cancer cells. T. Cerna, J. Hrabeta, T. Groh, S. Dostalova, H.V. Nguyen, A. Moullick, R. Kizek, V. Adam, M. Stiborova, **T. Eckschlager** (Prague; Brno, Czech Republic) (30')
491. Mechanisms of maintenance of genomic stability by BLM and RECQL4 helicases. **S. Sengupta** (New Delhi, India) (30')
490. Taste perception and oxidative DNA damage in healthy subjects and cancer patients: A pilot study. **L. Vodickova**, M. Carrai, D. Campa, J. Slyskova, S. Vodenkova, K. Jiraskova, A. Rejhova, M. Kroupa, V. Vymetalkova, I. Martelli, F. Canzian, L. Bavaresco, A. Bertelli, P. Vodicka, R. Barale (Prague; Pilsen, Czech Republic; Pisa; Conegliano; Milano, Italy; Heidelberg, Germany) (30')

## MOLECULAR ONCOLOGY/CLINICAL ONCOLOGY

Room C, 11:30-13:30  
Thursday, October 8

Chair Persons: H. Lane, Y. Ni

291. BAL101553 (prodrug of BAL27862): The 'Spindle Assembly Checkpoint (SAC)' is required for anti-cancer activity. K. Burger, F. Bachmann, **H. Lane** (Basel, Switzerland) (30')
311. Chemoradioablation of solid malignancies by sequential systemic administration of two small targeting molecules. **Y. Ni** (Leuven, Belgium) (30')
399. Clinical proteomics in oncology: Accurate prediction of molecular response in chronic myeloid leukemia (CML) patients as a model for personalized medicine. **A.A. Alaiya** (Riyadh, Saudi Arabia) (30')
262. *SEL1L* SNP rs12435998, a predictor of glioblastoma survival and response to radio-chemotherapy. **M. Mellai**, M. Cattaneo, L. Annovazzi, A.M. Storaci, P. Cassoni, A. Melcarne, P. De Blasio, D. Schiffer, I. Biunno (Vercelli; Milan; Turin, Italy) (15')
263. Glioblastoma: Microenvironment, niches and intrinsic regulatory mechanisms. **D. Schiffer**, L. Annovazzi, M. Mazzucco, M. Mellai (Vercelli, Italy) (15')

## IMMUNOLOGY/MOLECULAR ONCOLOGY

Room C, 15:30-17:30  
Thursday, October 8

Chair Persons: S.N. Karagiannis, T. Gräslund

341. B cell and antibody responses in solid tumours: Focus on cutaneous melanoma and implications for cancer immunotherapy. **S.N. Karagiannis** (London, UK) (30')
474. Affibody molecules: Therapy and *in vivo* diagnostic applications. **T. Gräslund** (Stockholm, Sweden) (30')
388. Humanized mouse models for cancer immunotherapy. **P. Kaur**, J. Keck (Sacramento, CA, USA) (30')
231. NK and CD4<sup>+</sup> cells are important for the development of protective immunity, growth and regression of experimental tumours. **M. Indrová**, I. Štěpánek, A. Fišerová, J. Richter, J. Bieblová, J. Šímová, J. Rossowska, E. Pajtasz-Piasecka, M. Reiniš (Prague; Kladno, Czech Republic; Wrocław, Poland) (15')
208. TLR2-induced autophagy regulates hepatoma-polarized M2 macrophage differentiation. D.-J. Shiau, **C.-P. Chang** (Tainan, Taiwan, R.O.C.) (15')

## CHEMOTHERAPY/PHARMACOLOGY

Room C, 18:00-20:00  
Thursday, October 8

Chair Persons: P. Fishman, D. Fregona

380. The anti-liver cancer drug CF102 protects against hepatic ischemia-reperfusion injury. G. Ohana, S. Cohen, L. Rath-Wolfson, **P. Fishman** (Petach-Tikva, Israel) (30')
393. New metal-based cancer-targeting chemotherapeutics. C. Nardon, **D. Fregona** (Padova, Italy) (30')
476. Gingerols and cucurbitacins as new chemosensitizers for resistant breast and ovarian cancer. **F.A. Badria**, M.H. El-Naggar, F.M. Abdel Bar, F.F. El-Senduny, F. Halaweish, A.S. Ibrahim, A.M. EL-Waseef (Mansoura, Egypt; Brookings, SD, USA) (30')
150. Aspirin acetylates multiple cellular proteins including p53: Implications for chemotherapy. **L.F. Alfonso** (Buffalo, NY, USA) (15')
218. Clinical significance of genetic variations of Hippo-YAP pathway-related genes in hepatocellular carcinoma. **Z. Xu**, L. Shen, J. Chen (Nanjing, P.R. China) (15')

## MOLECULAR MEDICINE/PHARMACOLOGY

Room D, 09:00-11:00  
Thursday, October 8

Chair Persons: M. Firer, L. Ulloa

209. Design and selection of appropriate peptide-drug conjugates for targeted drug delivery. **M. Firer**, G. Luboshits, J. Gilad, G. Gellerman (Ariel, Israel) (30')
246. Translating neuromodulation into molecular medicine. **L. Ulloa**, Z. Li, P. Morcillo, R. Torres-Rosas (Newark, NJ, USA) (30')
183. Upregulation of RBFOX1 in the malformed cortex of patients with intractable epilepsy and in cultured rat neurons. **M. Wen**, Y. Yan, N. Yan, X. Chen, S.Y. Liu, Z. Feng (Chongqing; Xi'an; Guiyang, P.R. China) (25')
200. Dysregulation of circulating endothelium-enriched microRNA-126 in type 2 diabetes mellitus patients with cardiovascular disease and diabetic nephropathy. **G. Al-Kafaji**, H.A. Al-Muhtaresh (Manama, Kingdom of Bahrain) (20')
261. Chemotherapeutic drugs in glioblastoma cell lines: DNA damage and repair cascade. **L. Annovazzi**, M. Mellai, D. Schiffer (Vercelli, Italy) (15')

## MOLECULAR MEDICINE

Room D, 11:30-13:30  
Thursday, October 8

Chair Persons: K. Ohlendieck, M. Wang

210. Proteomic profiling of muscular dystrophy-associated fibrosis. S. Murphy, A. Holland, P. Dowling, **K. Ohlendieck** (Maynooth, Ireland) (30')
277. Study on the regulatory mechanism of cystathionine  $\gamma$ -lyase gene. **M. Wang**, R. Shi, L. Cai, C. Xu (Chaozhou, P.R. China) (30')
299. Magnesium deficiency regulates magnesium transporter gene expression and impairs bone fracture healing. Y.-C. Chiu, H.-Y. Chen, **F.-C. Cheng** (Taichung, Taiwan, R.O.C.) (30')
390. A comparative study of serum zinc concentration and immune system functions in symptomatic venous thromboembolism patients. **S. Wen**, F. Yang, L. Wang (Shanghai, P.R. China) (15')
391. Comparative study of gene expression of integrin  $\beta$ 2 between acute myocardial infarction and stable angina pectoris patients. **S. Wen**, Y. Jin, L. Wang (Shanghai, P.R. China) (15')

## MOLECULAR MEDICINE

Room D, 15:30-17:30  
Thursday, October 8

Chair Persons: J.M. Casasnovas, R. Massoumi

339. Allosteric inhibition of aminopeptidase N functions through the suppression of ectodomain motions. C. Santiago, G. Mudgal, **J.M. Casasnovas** (Madrid, Spain) (20')
359. Regulation of Wnt signaling in development and diseases. H. Ke, K.C. Masoumi, K. Ahlqvist, M.J. Seckl, K. Rydell-Törmänen, **R. Massoumi** (Lund, Sweden; London, UK) (20')
360. Endometrial expression of molecular markers during implantation window: A new era in the diagnostic approach of endometrial receptivity. **S. Petousis** (Thessaloniki, Greece) (20')
409. Human plasma kallikrein-kinin system is regulated by endocytosis: The role of proteoglycans. **G. Motta**, I.L.S. Tersariol (São Paulo, Brasil) (20')
555. Aurora-A kinase activity is essential for anaphase. D. Rebutier, **C. Prigent** (Rennes, France) (20')
556. Aurora-A and spindle assembly checkpoint. A. Diallo, D. Rebutier, E. Watrin, **C. Prigent** (Rennes, France) (20')

## CARCINOGENESIS/MOLECULAR ONCOLOGY

Room D, 18:00-20:00  
Thursday, October 8

Chair Persons: C. Laurent, R.Y. Abu Seir

473. Radiation-induced oxidative stress in normal human skin fibroblasts after carbon ion irradiation compared with X-ray exposure. **C. Laurent**, A. Leduc, I. Pottier, V. Prévost, S. Lagadu, J.-L. Lefaix, F. Sichel (Caen, France) (30')
467. Cancer status in Palestine: Epidemiology and research experience. **R.Y. Abu Seir**, A.T. Kharroubi (Jerusalem, Palestine) (30')
366. Biosimilar erythropoietin alpha is effective as originator erythropoietin alpha plus liposomal iron, B12 and folates in patients with refractory anemia: A retrospective real-life approach. **G. Giordano**, P. Mondello, R. Tambaro, N. Perrotta, F. D'Amico, A. D'Aveta, G. Berardi, B. Carabellese, A. Patriarca, G.M. Corbi, L. Di Marzio, A. Licianci, D. Berardi, L. Di Lullo, R. Di Marco (Campobasso; Messina; Napoli; Chieti; Biella; Rome, Italy) (15')
273. The effects of Hashimoto's thyroiditis with lymphocytic infiltration on BRAF<sup>V600E</sup> mutation positive papillary thyroid carcinoma. **M.K. Shin**, J.W. Kim (Seoul, Republic of Korea) (15')
465. Intensity-modulated radiation therapy versus 2D-RT or 3D-CRT for the treatment of nasopharyngeal carcinoma. **B. Zhang**, M. Li, Y. Wang, L. Liu, Y. Wei (Chengdu, P.R. China) (15')
226. Interleukin 6-triggered ataxia-telangiectasia mutated activation facilitates lung cancer metastasis via MMP-3/MMP-13 upregulation. Y.N. Jiang, H.Q. Yan, X.B. Huang, Y.N. Wang, **F.G. Gao** (Xiamen; Shanghai, P.R. China) (15')



## BIOMARKER DISCOVERY

Room E, 09:00-11:00  
Thursday, October 8

Chair Persons: D. Gomez, L. Huo, W. Li

547. New inhibitors of telomerase. R.G. Armando, D.M. Gomez, **D. Gomez** (Buenos Aires, Argentina) (20')
430. Diagnostic immunohistochemical markers in breast cancer metastasis. **L. Huo** (Houston, TX, USA) (20')
516. A novel human TINP1 gene promotes cell proliferation by inhibition of p53 and p21 expression. **W. Li**, Y. Hu, A. Song (Jinan, P.R. China) (20')
431. Role of NOS2 and COX2 as driver of poor prognosis in basal-like breast cancer. **D. Basudhar**, L.A. Ridnour, R.Y. Cheng, D.A. Wink (Frederick, MD, USA) (15')
239. Non-synonymous functional variants in DNA repair genes in sporadic colorectal cancer: Searching for predictive and prognostic markers. **K. Jiraskova**, J. Slyskova, F. Rosa, V. Vymetalkova, B. Pardini, P. Vodicka (Prague, Czech Republic; Turin, Italy) (15')
158. FoxM1-uPA/uPAR signal in pancreatic cancer EMT and metastasis. **C. Huang**, Z. Qiu, K. Xie (Shanghai, P.R. China; Houston, TX, USA) (15')
361. Validation of survival-associated biomarkers in solid tumors using publicly available gene chip and next generation sequencing data. **B. Györfy**, L. Pongor, Á. Nagy, Z. Sztupinszki (Budapest, Hungary) (15')

## GYNECOLOGICAL CANCER/THERAPEUTICS

Room E, 11.30-13.30  
Thursday, October 8

Chair Persons: M.T. Neves-Petersen, G. Xu

405. Towards a new photonic cancer therapy: Stopping cancer cell activation, migration and metastases using light. C.M. Botelho, V. Thiagarajan, R. Marques, S.B. Petersen, A. Gomes, H. Vorum, **M.T. Neves-Petersen** (Minho, Portugal; Tiruchirappalli, India; Aalborg, Denmark) (25')
377. Role of non-coding RNAs in chemoresistance in ovarian cancer. **G. Xu** (Shanghai, P.R. China) (25')
403. The importance of the sulfatase pathway for local estrogen formation in endometrial cancer. **T. Lanišnik Rižner**, M. Sinreih, M. Anko, N. Hevir-Kene, K. Vouk, T. Šmuc, J. Šinkovec, A. Jerin, S. Frković-Grazio (Ljubljana, Slovenia) (20')
552. Telomere length in peripheral blood leukocytes and cancer risks: A tale of long and short. **J. Gu** (Houston, TX, USA) (20')
478. Antitumour activity of the desmopressin analogue [V<sup>4</sup>Q<sup>5</sup>]dDAVP as a single agent and in combination with chemotherapy in aggressive V2r-expressing breast carcinoma models. **J. Garona**, M. Pifano, M.B. Pastrian, N.B. Iannucci, D.E. Gomez, G.V. Ripoll, D.F. Alonso (Buenos Aires, Argentina) (15')
436. Metastatic lymph node fibroblasts maintain similar profile of stromal biomarkers registered in primary breast carcinomas. **F.G.L. Mundim**, F.S. Pasini, S. Nonogaki, F.A. Soares, M.M. Brentani, A.F. Logullo (São Paulo, SP, Brazil) (15')

## DIAGNOSTICS/BIOMARKERS

Room E, 15:30-17:30  
Thursday, October 8

Chair Persons: M. Grusch, R. Veselska, S.S. Signorelli

110. Optogenetic tools for new approaches in oncology research. K. Schelch, A. Ingles-Prieto, E. Reichhart, S. Gingl, H. Janovjak, **M. Grusch** (Vienna; Klosterneuburg, Austria) (25')
367. Cancer stem cell markers in pediatric sarcomas: Comparative analysis of their expression in tumor tissues and derived cell lines. **R. Veselska**, J. Skoda, A. Nunukova, T. Loja, I. Zambo, J. Neradil, M. Hermanova, P. Mudry, K. Zitterbart, D. Zapletalova, M. Kyr, J. Jaros, A. Hampl, J. Sterba (Brno, Czech Republic) (25')
482. New potential biomarkers for monitoring tissue ischemia in peripheral arterial disease. **S.S. Signorelli** (Catania, Italy) (20')
554. Novel targets of tumor suppressor p53 in breast tumorigenesis and cancer metastasis. **H. Chander** (Bathinda, India) (20')
481. Tumor microenvironment in non-Hodgkin's lymphoma. M. Libra, **A. Garozzo**, D. Cinà, F. Pezzino, G. Malaponte, S. Travali (Catania, Italy) (15')
175. Evaluation of tumor metastasis-associated markers for molecular classification in patients with esophageal squamous cell carcinoma. **J.-X. Huang**, G.-H. Han, M. Lin, W. Xiao, M.-S. Lin, H. Yu, P. Chen, R.-Y. Qian (Taizhou, P.R. China) (15')

## DIAGNOSTICS/BIOMARKERS

Room E, 18:00-20:00  
Thursday, October 8

Chair Persons: A. Dimitrakopoulou-Strauss, T.V. Byzova

204. PET-based molecular imaging using Ga-68-labeled peptides in oncological patients. **A. Dimitrakopoulou-Strauss** (Heidelberg, Germany) (25')
472. Platelets in cancer. **T.V. Byzova** (Cleveland, OH, USA) (25')
517. Discovery of  $\alpha$ -mangostin as a novel competitive inhibitor against mutant isocitrate dehydrogenase-1. H.-J. Kim, **Y.-S. Keum** (Goyang, Republic of Korea) (25')
488. Tumor biology in older breast cancer patients - what is the impact on survival stratified for guideline adherence? A retrospective multi-center cohort study of 5378 patients. **F. Ebner**, K. Hancke, M. Blettner, L. Schwentner, A. Wöckel, R. Kreienberg, W. Janni, R. van Ewijk (Ulm; Mainz; Würzburg, Germany) (15')
363. Mitochondrial DNA and carcinogenesis. **L. Grzybowska-Szatkowska**, B. Ślaska, D. Bańkowska-Polak, K. Szatkowski (Lublin, Poland) (15')
270. Advances in metastatic pancreatic cancer. **N. Kentepozidis** (Athens, Greece) (15')

## EXPERIMENTAL THERAPEUTICS

Room A, 09:00-11:00  
Friday, October 9

Chair Persons: Y.M. Rustum, B. Bonavida

177. Modulation of transcription factors regulated by HIFs: An approach to the development of new and novel therapy for cancer. **Y.M. Rustum** (Buffalo, NY, USA) (30')
224. *In silico* tissue-based expression analysis of YY1 and cancer stem cell transcription factors in hematological and solid tumors: Deciphering new therapeutic targets. S. Kaufhold, A. Shvartsur, H. Garban, **B. Bonavida** (Los Angeles, CA, USA) (30')
271. Targeting  $\beta$ -catenin pathway in hepatocellular carcinoma by TRAIL combination therapy. S. Santha, I. Khan, A. Rana, **B. Rana** (Maywood, IL; Hines, IL, USA) (30')
510. RNase P, a potential therapeutic tool for the inhibition of cancer genes: The case of the WRN helicase. A. Hitrik, **N. Jarrous** (Jerusalem, Israel) (30')

## AUTOPHAGY/MOLECULAR ONCOLOGY

Room A, 11:30-13:30  
Friday, October 9

Chair Persons: R. Ketteler, N. Rivard

250. A CRISPR view on autophagy gene regulation. N. Pengo, A. Agrotis, K. Prak, **R. Ketteler** (London, UK) (30')
455. Regulation of the master regulator of autophagy and lysosomal biogenesis TFEB by the glycogen synthase kinase-3 (GSK3). B. Marchand, D. Arsenault, **M.-J. Boucher** (Sherbrooke, Canada) (30')
460. Oncogenic KRAS promotes the Wnt/ $\beta$ -catenin signaling pathway through LRP6 during colorectal oncogenesis. **N. Rivard**, É. Lemieux (Sherbrooke, Canada) (30')
104. Untamed mTOR activity in human melanoma cells. D. Calianese, G. Cammarata, C. Best, **Y. Wan** (Providence, RI, USA) (30')

## EXPERIMENTAL THERAPEUTICS

Room A, 15:30-17:30  
Friday, October 9

Chair Persons: L. Wang, O.A. Martin, M. Lopus

189. Targeting breast cancer stem cells. D. Jia, L. Li, Y. Tan, S. Ooi, A. Sulaiman, **L. Wang** (Ottawa, Canada) (30')
496. Monitoring DNA damage response to predict radiotherapy-related normal tissue toxicity. P. Lobachevsky, T. Leong, P. Daly, I.G. Campbell, E.R. Thompson, N. Li, J. Smith, N. Best, R.F. Martin, **O.A. Martin** (Melbourne, Australia) (30')
116. Advances in tubulin-targeted cancer chemotherapeutics. **M. Lopus** (Mumbai, India) (30')
289. Infection of tumor cells with bacteria alters their response to anti-topoisomerase drug. R. Afriat, Y. Mizrahi Nebenzahl, **E. Priel** (Beer Sheva, Israel) (30')

## THERAPEUTICS/TUMOR MICROENVIRONMENT

Room A, 18:00-20:00  
Friday, October 9

Chair Persons: H. Modjtahedi, M. Danilenko

374. Targeting of tumour cells with acquired resistance to anti-EGFR antibody. S.A. Khelwatty, S. Essapen, A.M. Seddon, Z. Fan, **H. Modjtahedi** (London; Guildford, UK; Houston, TX, USA) (30')
321. Combinations of natural compounds with distinct mechanisms of action as efficacious antileukemic agents. S. Pesakhov, V. Novik, M. Nachliely, Y. Sharoni, D. Fishman, G.P. Studzinski, **M. Danilenko** (Beer Sheva, Israel; Newark, NJ, USA) (30')
373. Role of FAK in migration and invasion processes. P. Carl, T.B. Deramautd, K. Kolli-Bouhafs, F. Noulet, D. Dujardin, E. Sick, **P. Rondé** (Strasbourg, France) (30')
425. Expression of circadian rhythm genes is disrupted by the tumor microenvironment and promotes the development of hepatocellular carcinoma. **S.-L. Yang**, G. Wu, Z.-Y. Li, X. Fang, G.G. Chen, P.B.S. Lai (Wuhan; Hong Kong, P.R. China; Gainesville, FL, USA) (30')

## MOLECULAR ONCOLOGY

Room B, 09:00-11:00  
Friday, October 9

Chair Persons: C. Dai, D.L. Vesely, A.M. Kleinman

422. Guarding cancer proteomic stability by the HSF1-mediated proteotoxic stress response. Z. Tang, S. Dai, Y. He, R.A. Doty, L.D. Shultz, S.B. Sampson, **C. Dai** (Bar Harbor, ME, USA) (30')
103. Family of cardiac peptides with anticancer effects. **D.L. Vesely** (Tampa, FL, USA) (30')
515. The basic science and mathematics of random mutation and natural selection. **A.M. Kleinman** (Coarsegold, CA, USA) (30')
165. Identification of 5-hydroxymethylated loci as potential novel biomarkers in liver cancer. M. Muffadal, J. Wang, T. Motiwala, D. Frankhouser, P. Yan, S.T. Jacob, **V.X. Jin**, K. Ghoshal (Columbus, OH; San Antonio, TX, USA; Oslo, Norway) (15')
518. Preventive care for malignancies using microRNAs as therapeutic tools in the context of pre-cancerous stem cells. **G. Glady** (Colmar, France) (15')

## SIGNALING/PHARMACOLOGY

Room B, 11:30-13:30  
Friday, October 9

Chair Persons: J.A. McCubrey, J. Petschnigg

244. Targeting signaling pathways involved in metastasis in cancer stem cells. **J.A. McCubrey**, S.H. Abrams, W.H. Chappell, T.L. Fitzgerald, K. Lertpiriyapong, J. Polesel, A.M. Martelli, M. Cervello, G. Montalto, S. Candido, M. Libra, L.S. Steelman (Greenville, NC, USA; Aviano; Bologna; Palermo; Catania, Italy) (30')
245. Functions of NGAL and GSK-3beta in sensitivity to targeted, chemo- and hormonal-based therapies. **L.S. Steelman**, S.L. Abrams, W.H. Chappell, T.L. Fitzgerald, K. Lertpiriyapong, J. Polesel, A.M. Martelli, M. Cervello, G. Montalto, S. Candido, M. Libra, J.A. McCubrey (Greenville, NC, USA; Aviano; Bologna; Palermo; Catania, Italy) (30')
286. Identification of novel EGFR interactors involved in oncogenic signaling. **J. Petschnigg**, I. Stagljar, R. Ketteler (London, UK; Toronto, Canada) (30')
102. Restoration of desmosomal junction protein expression and inhibition of H3K9-specific histone demethylase activity by cytostatic, proline-rich polypeptide-1 leads to suppression of tumorigenic potential in human chondrosarcoma cells. **K. Galoian**, A. Qureshi, G. Wideroff, H.T. Temple (Miami, FL, USA) (30')

## GYNECOLOGICAL CANCER/THERAPEUTICS

Room B, 15:30-17:30  
Friday, October 9

Chair Persons: T.W. Grunt, N. Franken

181. Lipogenic metabolism in ovarian cancer cells and its non-malignant precursors. D. Veigel, R. Wagner, G. Stübiger, M. Filipits, R. Horvat, P. Valent, M. Grusch, **T.W. Grunt** (Vienna, Austria) (30')
123. Modulation of combined hyperthermia - Radiation treatment for cervical carcinoma. A. Oei, C. van Leeuwen, L. Stalpers, H. Rodermond, H. Crezee, P. Kok, **N. Franken** (Amsterdam, The Netherlands) (30')
156. Pelvic exenteration for loco-regionally invasive cervical cancer - Current challenges. **N. Bacalbasa**, I. Balescu (Bucharest, Romania) (15')
159. Role of ER stress on cisplatin resistance in human ovarian cancer cells. **Y. Xu**, H. Yu, J. Su, L. Ma, Q. Xie, J. Kang, H. Li, Z. Li, L. Sun (Changchun, P.R. China) (15')
236. Natural history of recurrences in endometrial carcinoma. B. Sorbe, **C. Juresta**, C. Ahlin (Örebro, Sweden) (15')
281. Ovarian cancer: The role of side population cells. **A. Meeson** (Newcastle, UK) (15')

## MOLECULAR MEDICINE

Room B, 18:00-20:00  
Friday, October 9

Chair Persons: S. van Slambrouck, Y. Tandler

109. Aberrant glycosylation and membrane disorganization in metastatic prostate cancer. **S. van Slambrouck** (Brookings, SD, USA) (25')
463. Possible reason for p53 accumulation in the cytoplasm of corneal epithelial cells. **Y. Tandler**, R. Pokroy, A. Panshin (Haifa; Be'er Ya'akov; Beit Dagan, Israel) (25')
428. Mitochondrial catastrophe during DXR-induced cardiotoxicity: The protective role of MLT. **J. Govender**, B. Loos, F. van der Westhuizen, A.-M. Engelbrecht (Stellenbosch; Potchefstroom, South Africa) (15')
148. An association between polymorphism in CA repeat in 5' promoter region of IGF 1 and risk of endometrial cancer development. **W. Kwasniewski**, A. Gozdicka-Jozefiak, M. Wolun-Cholewac, J. Sierocińska-Sawa, M. Kotarska, J. Kotarski (Lublin; Poznan, Poland; Chicago, IL, USA) (15')
347. Predicting risk of progression for oral potentially malignant lesions: From validation of a 'toolbox' to clinical application. **M. Rosin**, D. Laronde, N. Schuurman, L. Zhang, M. Guillaud, C. MacAulay (Vancouver; Burnaby, Canada) (15')
392. Differential expression of T cell-related genes in patients with paroxysmal atrial fibrillation and stable angina pectoris. **Y. Jin**, L. Wang, Q. Duan, S. Wen, C. Li, H. Song (Shanghai, P.R. China) (15')
194. Mitochondrial complex II is a source of the reserve respiratory capacity that is regulated by metabolic sensors and promotes cell survival. **J. Pfleger**, M. He, M. Abdellatif (Newark, NJ, USA) (10')

## EXPERIMENTAL THERAPEUTICS

Room C, 09:00-11:00  
Friday, October 9

Chair Persons: S.J. Beebe, P. Soucek, N. Zöller

126. Nanosecond pulsed electric field ablation of hepatocellular carcinoma induces regulated cell death and possible immunity. **S.J. Beebe**, R. Chen, P.K. Shires, R. Heller (Norfolk, VA; Cincinnati, OH, USA) (25')
127. Possible effects of nanosecond pulsed electric fields on proteins. **S.J. Beebe** (Norfolk, VA, USA) (25')
514. The role of oxysterol pathway modifying genes in breast carcinoma progression. **P. Soucek**, A. Kloudova, V. Brynychova, V. Hlavac, D. Vrana, K. Kubackova, J. Gatek, F.P. Guengerich, Y.-F. Ueng (Prague; Olomouc; Zlin, Czech Republic; Nashville, TN, USA; Taipei, Taiwan R.O.C.) (25')
128. Curcumin, spicing up the treatment of actinic keratosis and epidermal tumors. **N. Zöller**, J. Dujic, S. Buss, V. Laubach, A. Ramirez-Bosca, S. Kippenberger, R. Kaufmann, A. Bernd (Frankfurt, Germany; Elche, Spain) (15')
336. CF102, an A<sub>3</sub> Adenosine Receptor Agonist, from *in vitro* to clinical trials. **S. Cohen**, P. Fishman (Petach-Tikva, Israel) (15')
543. Personalized therapy for chronic lymphocytic leukemia. **M. Rogalińska**, J. Błoński, P. Góralski, P. Robak, I. Franiak-Pietryga, E. Wawrzyniak, A. Rogalska, H. Maciejewski, A. Koceva-Chyła, H. Piekarski, T. Robak, Z.M. Kilianska (Lodz; Wroclaw, Poland) (15')

## INFLAMMATION/DIFFERENTIATION

Room C, 11:30-13:30  
Friday, October 9

Chair Persons: T.L. Roberts, N.-S. Yang

276. The roles of SMG1 and ATM in stress responses, inflammation and blood cancers. **T.L. Roberts**, U. Ho, J. Luff, A. James, S. Apte, H. Quek, M.F. Lavin (Liverpool; Herston, Australia) (20')
229. Effect of anti-inflammatory and anti-cancer activities of phytochemicals from traditional herbal medicines as revealed by omics approaches. **N.-S. Yang** (Taipei, Taiwan, R.O.C.) (20')
538. AID/APOBECs linking immunity, chronic inflammation and cancer: From expression to disease pathobiology. **D. Mechtcheriakova** (Vienna, Austria) (20')
160. Protective role of ulinastatin on lung injury and inflammation induced by hemorrhagic shock. **T. Takahashi**, K. Inoue (Okayama; Takamatsu, Japan) (15')
186. In women with endometriosis, ovarian cancer markers CA125 and HE4 in peritoneal fluid are correlated to ovarian lesion location while inflammatory cytokines are not. **N.A. Bersinger**, D. Bertschi, B. McKinnon, M.D. Mueller (Berne, Switzerland) (15')
303. Chemopreventive effects of nonsteroidal anti-inflammatory drugs and the risk of fatal lung cancer. **M.A. Bittoni**, R.E. Harris (Columbus, OH, USA) (15')
406. Anti-inflammatory and antitumor effects of a new drug combination for colitis-associated colorectal cancer. G. Figueroa, **C. Pérez-Plasencia** (Mexico) (15')

## BREAST CANCER

Room C, 15:30-17:30  
Friday, October 9

Chair Persons: D. Marchetti, Y. Gong, A. Kontrogianni-Konstantopoulos

118. Dissecting CTC phenotypes: Insights into mechanisms of breast cancer dormancy. M. Vishnoi, S. Peddibhotla, W. Yin, A. Scamardo, D. Hong, **D. Marchetti** (Houston, TX, USA) (30')
197. Stability of prognostic and predictive biomarkers of breast cancer. **Y. Gong** (Houston, TX, USA) (30')
191. Giant obscurins: Novel tumor and metastasis suppressors in breast cancer. **A. Kontrogianni-Konstantopoulos** (Baltimore, MD, USA) (30')
108. The role of HAX1 protein in the regulation of cell invasive potential and breast cancer metastasis. A. Trebinska, L. Szafron, E. Macech, M. Chmielarczyk, S. Tabor, **E.A. Grzybowska** (Warsaw, Poland) (15')
155. Molecular and inflammatory signaling in breast cancer progression. E.S. Kim, Y. Cha, M. Ham, J. Jung, S.G. Kim, S. Hwang, R. Kleemann, **A. Moon** (Seoul, Republic of Korea; Leiden, The Netherlands) (15')

## BREAST CANCER/MOLECULAR ONCOLOGY

Room C, 18:00-20:00  
Friday, October 9

Chair Persons: M.A. Khajah, J.A. Pinto

114. Effect of alkaline pH on endocrine-resistant breast cancer cells. **M.A. Khajah**, P.M. Mathew, N.S. Alam-Eldin, Y.A. Luqmani (Safat, Kuwait) (30')
202. A prognostic 3-gene genomic score in triple-negative and basal-like breast tumors with residual disease. **J.A. Pinto**, J. Araujo, N.K. Cardenas, Z. Morante, F. Doimi, T. Vidaurre, J.M. Balko, H.L. Gómez (Lima, Peru; Nashville, TN, USA) (15')
107. Leptin receptor-dependent and -independent STAT3 phosphorylation in oestrogen receptor-negative breast cancer. **H. Alshaker**, J. Krell, A.E. Frampton, Q. Wang, C. Cooper, M. Winkler, E. Yagüe, D. Pchejetski (Amman, Jordan; London; Norwich, UK) (15')
113. *eNOS* genetic polymorphisms and cancer risk: Evidence from a meta-analysis and a case-control study of breast cancer. **X. Gao**, W. Wang, J. Wang, M. Wang, J. Zhang (Nanjing; Bengbu, P.R. China) (15')
240. Frequency of cMet aberration in triple negative breast cancers. **H. Zhang** (Houston, TX, USA) (15')
247. The inhibition of mTOR and LDH-A leads to tumor growth inhibition in a triple negative breast cancer xenotransplant. **N.J. Jacobo-Herrera**, C. Pérez-Plasencia, V. García-Castillo, O. Villanueva-Sánchez, M.Á. Ávila-Rodríguez, A. Zentella-Dehesa (México) (15')
269. Up-regulation of microRNA-329 suppresses tumor progression in human breast cancer. **H. Kang**, C. Kim, J.G. Rho, W. Kim, E.K. Lee (Seoul; Suwon, Republic of Korea) (15')



## HEMATOLOGICAL MALIGNANCIES/MOLECULAR ONCOLOGY

Room D, 09:00-11:00  
Friday, October 9

Chair Persons: J. Mahajna, X. Sun

185. Potential use of allosteric inhibitors as strategy to overcome drug resistance in Ph-positive leukemia. A.A. Mian, I. Haberbosch, N. Kidan, H. Khamaisie, O. Regev, M. Nickola, M. Gal, E. Bloch, A. Rafiei, D. Silani, O.G. Ottmann, R. Biondi, M. Ruthardt, **J. Mahajna** (Kiryat Shmona, Israel; Frankfurt, Germany) (30')
196. Targeting IL-7/IL-7R pathway to overcome TKI-induced MSC-mediated resistance in BCR-ABL<sup>+</sup> acute lymphoblastic leukemia. S. Mallampati, J. Zeng, J. Li, **X. Sun** (Houston, TX, USA) (30')
198. Efficiency of BH3 mimetics targeting Bcl-2 in mature B cell malignancies: From sensitivity to acquired resistance. **M. Amiot**, D. Chiron, C. Touzeau, C. Dousset, S. Maïga, P. Moreau, L. Krauss-Berthier, C. Pellat-Deceunynck, S. Le Gouill (Nantes; Suresnes, France) (30')
149. The role of the microenvironment in the development of Burkitt lymphoma. **M. Mushtaq**, G. Klein, E. Kashuba (Stockholm, Sweden; Kyiv, Ukraine) (15')
164. MAGE C1 antigen expression in Multiple Myeloma: A tool for malignant cell identification, disease monitoring and determining disease mechanisms. **K. Wienand**, K. Shires (Cape Town, South Africa) (15')

## LUNG CANCER/BRAIN TUMORS

Room D, 11:30-13:30  
Friday, October 9

Chair Persons: A. Meshcheryakova, C. Solomides

255. Sphingolipid machinery in EMT: From a cell-based model to pathobiology of lung cancer. **A. Meshcheryakova**, M. Svoboda, H.C. Köfeler, A. Triebel, F. Mungenast, A. Tahir, C. Gerner, P. Zimmermann, M. Jaritz, D. Mechtcheriakova (Vienna; Graz, Austria; Zürich, Switzerland) (30')
468. Lung cancer: From tissue diagnosis to molecular testing. **C. Solomides** (Philadelphia, PA, USA) (30')
234. Differential expression and significance of plasma long non-coding RNAs in non-small cell lung cancer. **Q. Chen**, X. Dai, H. Li, B. Li, X. He, J. Gao, X. Si, X. Liu, B. Zhu, Y. Dang, Y. Ma, M. Li, S. Yuan (Xianyang, P.R. China) (15')
344. Detection and characterization of actionable mutations and deregulated pathways in lung adenocarcinoma for personalized medicine from NGS data. **Z. Sun**, A. Bhagwate, P. Vedell, J. Evans, N. Prodduturi, J. Jang, P. Yang, J. Yi, J. Jen (Rochester, MN, USA) (15')
378. Role of glutathione peroxidase 1 in cisplatin chemoresistance in non-small cell lung cancer. X. Gan, Z. Shen, X. Xie, X. Xu, R. Ou, D. Wu, **J. Chen**, B. Chen (Guangzhou, P.R. China) (15')
424. Identifications of the germline mutations and applications in precision medicine of lung adenocarcinoma. **H.-Y. Chen** (Taipei, Taiwan, R.O.C.) (15')

## COLON CANCER

Room D, 15:30-17:30  
Friday, October 9

Chair Persons: S. Savas, P. Vodička

170. A genome-wide survival study on colorectal cancer. W. Xu, J. Xu, K. Shestopaloff, E. Dicks, J. Green, P. Parfrey, R. Green, **S. Savas** (Toronto; St. John's, Canada) (20')
471. From genetic makeup to complex phenotypic features: A lesson from sporadic colorectal cancer. **P. Vodička**, J. Slyšková, B. Pardini, A. Naccarati, P. Souček, L. Vodičková, V. Vymetálková, M. Svoboda, P. Bendová, K. Jirasková, L. Bártů, S. Vodénková, S. Landi, R. Kumar, F. Canzian, A. Foersti, K. Hemminki (Prague; Pilsen, Czech Republic; Pisa; Turin, Italy; Heidelberg, Germany) (20')
545. Effect of onion flavonoids on colorectal cancer with hyperlipidemia: An *in vivo* study. **H. Jin**, Y. He, W. Gong, C. Zhang, A. Zhou (Nanjing; Jiangyin, P.R. China) (20')
243. The role of phospholipid metabolism in colorectal cancers resistant to chemotherapy. A. Cotte, E. Limagne, A. Scagliarini, V. Aires, J.-P. Pais De Barros, P. Hillon, F. Ghiringhelli, **D. Delmas** (Dijon, France) (15')
356. The role of Bcl-3 in colorectal cancer. K. Saamathy, S. Björner, M. Johansson, G. Landberg, K. Jirstrom, R. Massoumi, **K. Masoumi** (Lund; Gothenburg; Malmö, Sweden) (15')
385. The prognostic value of the VEGFR1 and VEGFR2 combination in colorectal cancer-associated endothelial cells. **C. Koopmansch**, J. Allard, F. Hulet, X. Moles-Lopez, Y.-R. Van Eycke, C. Decaestecker, I. Salmon, N. D'Haene (Brussels; Gosselies, Belgium) (15')
420. Lithium chloride induces mesenchymal-to-epithelial reverting transition in primary colon cancer cell cultures. **V. Costabile**, F. Duraturo, P. Delrio, D. Rega, U. Pace, R. Liccardo, G.B. Rossi, R. Genesio, L. Nitsch, L. Avallone, P. Izzo, M. De Rosa (Naples, Italy) (15')

## GASTROINTESTINAL/PANCREATIC/BLADDER CANCER

Room D, 18:00-20:00  
Friday, October 9

Chair Persons: G. De Maio, S. Gurzu

429. Genetic characterization in the adenoma-carcinoma progression. **G. De Maio**, C. Rengucci, E. Zama, A. Casadei Gardini, M. Zucca, E. Scarpi, E. Petracci, C. Zingaretti, G. Foschi, M.M. Tumedei, C. Molinari, L. Saragoni, M. Puccetti, D. Amadori, W. Zoli, D. Calistri (Meldola; Milan; Forlì; Ravenna, Italy) (20')
134. Early gastric cancer: Diagnostic and therapeutic difficulties. **S. Gurzu**, T. Bara, T. Bara Jr, I. Jung (Tirgu-Mures, Romania) (20')
135. Particularities of pancreatic mucinous cystic neoplasms. **I. Jung**, T. Bara, T. Bara Jr, S. Gurzu (Tirgu-Mures, Romania) (20')
157. A case of renal cell carcinoma with metachronous metastasis to the contralateral adrenal gland and urinary bladder. **K. Wang**, J. Wang, J. Sun, D. Zhong, S. Tai, D. Xu, Y. Fan (Hangzhou; Shanghai, P.R. China) (15')
322. Contrast-enhanced ultrasound imaging and the therapeutic effects of dual targeted PTX-PLGA-mPEG nanocapsules in pancreatic cancer. J. Ma, L. Xing, M. Shen, **F. Li**, M. Zhu, L. Jin, Z. Li, F. Gao, Y. Su, Y. Duan, L. Du (Shanghai, P.R. China) (15')
421. TRPV1, 3 and 4 expression in human ulcerative colitis. **T. Rizopoulos**, E. Petrou-Papadaki, M. Assimakopoulou (Patras, Greece) (15')
475. Predicting recurrence in non-muscle invasive bladder cancer following instillation of chemotherapy: Interference with transcription factor TFAP2a leads to a decrease in chemosensitivity in bladder cancer. **Y. Xie**, G. Fan, C. Liu, J. Lei, M. Ye, Z. Xu, W.-Q. Han (Changsha, P.R. China) (15')

## BIOCHEMISTRY/MOLECULAR BIOLOGY

Room E, 09:00-11:00

Friday, October 9

Chair Persons: R. Gambari, M.R. Berger

502. Peptide nucleic acid-based targeting of microRNAs: Diagnostic and therapeutic applications. **R. Gambari** (Ferrara, Italy) (30')
506. Evidence for miRNA regulation of BCL11A gene expression. J. Gasparello, E. Fabbri, N. Bianchi, G. Breveglieri, C. Zuccato, G. Montagner, L.C. Cosenza, I. Lampronti, F. Salvatori, M. Borgatti, R. Gambari, **A. Finotti** (Ferrara, Italy) (20')
508. High levels of apoptosis induced in human glioma cell lines by combined treatment with antagomiR PNAs and pre-miRNA molecules. **E. Fabbri**, E. Brognara, G. Montagner, J. Gasparello, N. Bianchi, A. Finotti, G. Breveglieri, M. Borgatti, I. Lampronti, R. Milani, G. Cabrini, R. Gambari (Ferrara; Parma; Verona, Italy) (20')
292. The tumor suppressor RhoB is upregulated in response to the alkylphosphocholine erufosine in oral squamous cell carcinoma. S. Ansari, N. Akgün, **M.R. Berger** (Heidelberg, Germany) (20')
153. DNA methylation status of *RASSF1A* and *MGMT* in head and neck squamous cell carcinoma. V.R. Regiani, **C.H. Viési do Nascimento Filho**, G.H. Marucci, C.A. Rainho, D. Di Santi Neto, J.V. Maníglia, E.M. Goloni-Bertollo, É.C. Pavarino (São Paulo, Brazil) (15')
282. Improving TKI efficiency by IL-6 inhibition. K. Ishibashi, T. Haber, H. Kubo, Y. Kojima, J.W. Thüroff, **W. Brenner** (Fukushima, Japan; Mainz, Germany) (15')

## SIGNALING/TUMOR BIOLOGY

Room E, 11:30-13:30

Friday, October 9

Chair Persons: Q. Lin, E.A. Podrez

529. The role of astrocytes in the resistance of brain tumors toward chemotherapy. **Q. Lin**, S. Kim, K. Balasubramanian, G. Xu, I. Fidler (Beijing, P.R. China; Houston, TX, USA) (20')
498. Novel roles of Akt3 kinase. **E.A. Podrez** (Cleveland, OH, USA) (20')
345. Rpb3 promotes hepatocellular carcinoma through its N-terminus. **Z.-P. Fang**, B.-G. Jiang, F.-B. Zhang, A.-D. Wang, Y.-M. Ji, Y.-F. Xu, W.-P. Zhou, W.-J. Zhou, H.-X. Han (Linhai; Shanghai, P.R. China; Ann Arbor, MI, USA) (15')
330. Notch signaling in normal and tumor angiogenesis. **I. Dimova**, S. Ravikumar, A. Makanya, R. Hlushchuk, D. Nikolova, V. Djonov (Sofia, Bulgaria; Bern, Switzerland) (15')
259. Mutant p53 gain-of-function induces HER2 over-expression. **J. Díaz-Chávez**, A. Roman-Rosales, E. García-Villa, P. Gariglio, L.A. Herrera (México) (15')
351. Dll4-Notch signalling in glioblastoma. **Y. Zhu**, N. El Hindy, U. Sure (Essen, Germany) (15')
553. Neuroendocrine markers in lung cancer patients. M. Petrović, **V. Jurisić** (Kragujevac, Serbia) (10')
264. Long non-coding RNA SRA: A key suppressor of renal carcinoma on tumorigenesis and metastasis. Y. Ni, Y. Yin, C. Liu, S. Li, B. Huang, D. Liao, C. Qian, **L. Qin** (Changsha; Hengyang; Guangzhou, P.R. China) (5')
266. Insight into steroid receptor RNA activator: Expanded biological functions and signaling pathways. C. Liu, N. Zhu, Y. Ni, Z. Liu, B. Ao, S. Li, D. Liao, **L. Qin** (Changsha; Hengyang, P.R. China) (5')

MOLECULAR ONCOLOGY/microRNAs

Room E, 15:30-17:30  
Friday, October 9

Chair Persons: J.K. Fortson, E. Suzuki, O. Zoras

214. Nodular lymphocyte-predominant Hodgkin's lymphoma: A case report and review of literature. **J.K. Fortson**, R. Su (Atlanta, GA, USA) (20')
146. A role of trogocytosis of immune cells in breast tumor microenvironment. **E. Suzuki**, T.R. Kataoka, M. Hirata, K. Kawaguchi, M. Nishie, H. Haga, M. Toi (Kyoto, Japan) (20')
469. Hyperthermic isolated limb perfusion for locally recurrent melanoma of the limbs: Potential role of circulating tumor cells in disease outcome. D. Michelakis, I. Messaritakis, K. Lasithiotakis, C. Ioannou, I. Souglakos, D. Stamatou, K. Koronidou, E. De Bree, **O. Zoras** (Heraklion, Greece; York, UK) (20')
334. MicroRNA array analysis in colon cancer cells treated with antimicrobial peptides. **K. Kuroda**, T. Fukuda, H. Isogai, K. Okumura, E. Isogai (Sendai; Sapporo; Ishikari-Tobetsu, Japan) (15')
112. The expression and tumor-suppressor mechanism of microRNA-449a in non-small-cell lung cancer. **L. Bu**, L. Zhang, J. Peng, H. Peng, X. Chen, X. Mao, P. Wang (Kunming, P.R. China) (15')
462. Contrast-enhanced ultrasound (CEUS) in the therapeutic assessment of diffuse large B-cell lymphoma (DLBCL): A case report. **W. Du**, W. Ling, C. Jiang, J. Wang, X. Ma (Chengdu, P.R. China) (15')
133. Cannibalism of malignant melanoma cells as a consequence of their exposure to octocrylene. B. Zdravkovic, T. Prunk, B. Dariš, M. Lunder, B. Štrukelj, **P. Ferk** (Maribor; Ljubljana, Slovenia) (15')

MOLECULAR ONCOLOGY/microRNAs

Room E, 18:00-20:00  
Friday, October 9

Chair Persons: E. Rizos, J. Lee

523. The possible role of let-7, miR-98 and miR-181 as biomarkers of low cancer risk in schizophrenic patients. **E. Rizos**, N. Siafakas, E. Katsantoni, E. Skourti, V. Salpeas, I. Rizos, J. Tsoporis, A. Kastania, N. Xiros, T. Parker, C. Papageorgiou, V. Zoumpourlis (Athens, Greece; Toronto, Canada) (20')
252. Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy. M.C.A. Wouters, F.L. Komdeur, H.H. Workel, K.L. Brunekreeft, A. Plat, H.G. Klip, F.A. Eggink, G.B.A. Wisman, H.J.G. Arts, M.H.M. Oonk, M.J.E. Mourits, R. Yigit, M. Versluis, E.W. Duiker, E. Bremer, W. Helfrich, H. Hollema, H.W. Nijman, **M. De Bruyn** (Groningen, The Netherlands) (20')
201. Expression of circulating microRNA-1, microRNA-133, microRNA-192 and microRNA-377 in Bahraini patients with type 2 diabetes mellitus and its association with cardiac and renal complications. **H.A. Al-Muhtareh**, G. Al-Kafaji (Manama, Kingdom of Bahrain) (20')
283. Are miR-29 and miR-96 oncomirs or tumour suppressors? P.Y. He, W.K. Yip, **H.F. Seow** (Serdang, Malaysia) (20')
168. MiR-29b suppresses the proliferation, migration and invasion of tongue squamous cell carcinoma cells through PTEN-AKT signaling pathway by targeting Sp1. **L. Jia**, Y. Zheng, Y. Gan, G. Yu (Beijing, P.R. China) (20')
479. Fine tuning of natural killer cells by microRNAs in hepatocellular carcinoma. **H.M. El Tayebi**, M.A. Rahmoon, A.I. Abdelaziz (Cairo, Egypt) (20')

## THERAPEUTICS

Room A, 09:00-11:00  
Saturday, October 10

Chair Persons: G.M. Calaf, D. Roy

369. Targeting multiple genes in breast carcinogenesis. **G.M. Calaf**, M. Gallardo, R. Ponce-Cusi, T. Quispe, D. Roy (Arica, Chile; New York, NY; Bronx, NY, USA) (30')
370. Metastatic gene signature in breast carcinogenesis. **D. Roy**, G.M. Calaf (Bronx, NY; New York, NY, USA; Arica, Chile) (30')
121. Pathway analysis for personalized oncology. **A. Yuryev** (Rockville, MD, USA) (30')
531. Molecular pathology: Its impact on laboratory and patient safety. **M. Jiwa** (Alkmaar, The Netherlands) (30')

## BREAST CANCER

Room A, 11:30-13:30  
Saturday, October 10

Chair Persons: A. Rana, S.M. Hyder

324. Regulation of Mixed Lineage Kinase-3 (MAP3K11) and its role in breast cancer pathogenesis. S. Das, V. Rangasamy, R. Mishra, G. Sondarva, N. Viswakarma, R.S. Nair, C. Osipo, B. Rana, **A. Rana** (Chicago, IL; Hines, IL, USA) (30')
328. Inhibitors of oxidosqualene cyclase block growth and survival of both hormone-dependent and -independent breast cancer cells. Y. Liang, J. Aebi, **S.M. Hyder** (Columbia, MO, USA; Basel, Switzerland) (30')
280. Epithelial-to-mesenchymal transition: What is the impact on breast cancer stem cells and drug resistance. **P. Mallini**, T. Lennard, J. Kirby, A. Meeson (Newcastle, UK) (30')
331. Inhibition of the STAT6 pathway as a novel strategy to inhibit tumor-associated macrophage-induced tumor growth and metastasis in breast cancer. K.A. Binnemars-Postma, R. Bansal, G. Storm, **J. Prakash** (Enschede, The Netherlands) (30')

## EXPERIMENTAL THERAPEUTICS

Room A, 15:30-17:30  
Saturday, October 10

Chair Persons: H. Sarin, A.K. Larsen

301. Conserved molecular mechanisms underlying the effects of small molecule xenobiotic chemotherapeutics on cells. **H. Sarin** (Charleston, WV, USA) (30')
379. Molecular-targeted agents from bench to bedside: Erlotinib attenuates bevacizumab-mediated activation of EGFR-survival signaling in colorectal cancer (CRC) models independent of *KRAS* status providing a rational basis for the DREAM phase III clinical trial. **A.K. Larsen**, D. Muller, A. Bouygues, A. Savina, A. De Gramont, P. Mésange (Paris, France) (30')
353. Differential expression of RKIP-related genes in pre-multiple myeloma and multiple myeloma: A bioinformatics approach with clinical implications. A. Shvartsur, S. Kaufold, H. Garban, **B. Bonavida** (Los Angeles, CA, USA) (30')
524. An experimental strategy for *in vitro* discrimination between poisonous cytotoxic proapoptotic and selective non-proapoptotic natural compounds with potential anticancer activity. **R. Kiss**, A. Kornienko (Brussels, Belgium; San Marcos, TX, USA) (30')

## TUMOR BIOLOGY

Room A, 18:00-20:00  
Saturday, October 10

Chair Persons: C. Demonacos, M. Krstic-Demonacos, M.Z. Ratajczak

520. The role of cytochrome P450 family members in breast carcinogenesis. S. Singh, H. Alavi, M. Krstic-Demonacos, **C. Demonacos** (Manchester; Salford, UK) (30')
521. Molecular mechanisms of glucocorticoid hormone action. M. Sadeq, F. Ashtiani, C. Demonacos, **M. Krstic-Demonacos** (Salford; Manchester, UK) (30')
115. The embryonic rest hypothesis of cancer development - An old XIX century theory revisited in light of data that early development stem cells reside in dormant state in postnatal tissues. **M.Z. Ratajczak** (Louisville, KY, USA; Szczecin, Poland) (30')
513. Aurora inhibition: Synthetic lethal therapies for aggressive B-cell non-Hodgkin's lymphoma. **D. Mahadevan**, M.S. Islam, C. Morales, L. Cooke, M. Pandey, C. Spier, W. Qi (Memphis, TN; Tucson, AZ, USA) (30')

## PROSTATE CANCER

Room B, 09:00-11:00  
Saturday, October 10

Chair Persons: G. Perletti, L. Kotula

296. Efficacy of second-line agents for the treatment of metastatic castration-resistant prostate cancer progressing after docetaxel: Systematic review and meta-analysis. **G. Perletti**, E. Monti, A. Vral, A. Cleves, V. Magri, A. Trinchieri, P.S. Rennie (Busto Arsizio; Milano; Lecco, Italy; Ghent, Belgium; Cardiff, UK; Vancouver, Canada) (20')
383. Identification of the novel Abi1-WAVE pathway in castration-resistant prostate cancer. A.G. Sowalsky, R. Sager, R.J. Schaefer, G. Bratslavsky, P.P. Pandolfi, S.P. Balk, **L. Kotula** (Boston, MA, Syracuse, NY, USA) (20')
539. ARD1-mediated androgen receptor acetylation in prostate tumorigenesis. J. DePaolo, Z. Wang, J. Guo, C. Qian, **W. Liu** (New Orleans, LA, USA) (20')
172. TRP channel regulation during prostate carcinogenesis. **D. Gkika** (Lille, France) (20')
151. Atypical protein kinase C inhibition in prostate cancer cells: A study of ICA-1 and ACPD. A. Apostolatos, C. Apostolatos, **M. Acevedo-Duncan** (Tampa, FL, USA) (20')
106. Investigation of epigenetic markers in the loci of cancer-related genes for a prognostic blood test to predict prostate cancer risk. H. Alshaker, P. Jordan, A. Ramadass, M. Winkler, A. Akoulitchev, **D. Pchejetski** (Amman, Jordan; Oxford; London; Norwich, UK) (20')

## INFLAMMATION/MOLECULAR ONCOLOGY

Room B, 11:30-13:30  
Saturday, October 10

Chair Persons: A.M. Waaga-Gasser, M. Gasser

511. TLR inflammation-induced tumorigenesis and progression in colorectal cancer. **A.M. Waaga-Gasser** (Wuerzburg, Germany; Boston, MA, USA) (30')
512. The role of TLR7 and TLR8 expression in tumor cell proliferation and chemoresistance in pancreatic cancer. **M. Gasser** (Wuerzburg, Germany) (30')
333. SLE - Infection vs. inflammation: The effect of SLE sera on the expression of neutrophil surface molecules. **S. Malas** (London, UK) (20')
495. Clinical implications of RAR-beta methylation in cancer tissue and peripheral blood leukocytes of patients with lung cancer. **K.C. Ansley**, T. Dotson, G. Hawkins, W.J. Petty (Winston-Salem, NC, USA) (20')
519. New approaches to inhibiting breast cancer metastasis by repurposing drugs to control the prenylation and trafficking of small GTPases in breast cancer cells. J. Wilson, E. Lorimer, **C.L. Williams** (Milwaukee, WI, USA) (20')

## TUMOR BIOLOGY/CARCINOGENESIS

Room B, 15:30-17:30  
Saturday, October 10

Chair Persons: J.K. Fortson, H.K. Rooprai

215. Hurthle cell tumor of the thyroid: A case series. **J.K. Fortson**, R. Su, P.G. Bhat, S. Khurana (Atlanta, GA, USA) (30')
302. Polyphenols from *Aronia melanocarpa* enhance cytotoxicity of gemcitabine in a pancreatic cancer cell line, AsPC-1. N.A. Abdullah Thani, S. Keshavarz, B.A. Lwaleed, A.J. Cooper, **H.K. Rooprai** (London; Southampton; Portsmouth, UK) (15')
162. Abolish cancer progenitor/stem cells to restrict hepatocellular carcinoma initiation in nonalcoholic steatohepatitis. **Y. Li**, X. Li, H. Pandit, S. Li, S. Agle, J. Zhang, R.C. Martin (Louisville, KY, USA) (15')
192. Thyroid adenocarcinoma in two parrots. **C. Doukaki**, M.J.L. Kik, R. Ducatelle, H. Cornelissen, Y.R.A. van Zeeland (Utrecht; Nijmegen, The Netherlands; Merelbeke, Belgium) (15')
190. Virus and tobacco use in premalignant and malignant oral lesions. **L. Sand**, M. Jalouli, J. Jalouli, S. Ibrahim, B. Hasséus, J. Öhman, J.-M. Hirsch (Uppsala; Gothenburg, Sweden; Bergen, Norway) (15')
293. Erufosine affects the PI3K/AKT/mTOR axis and induces apoptosis in oral squamous cell carcinoma. **S.S. Ansari**, E. Ivanova, M.R. Berger (Heidelberg, Germany; Sofia, Bulgaria) (15')
335. Investigating the function of the AHNAK protein in doxorubicin resistance. **T. Davis**, B. Loos, J. Peres, S. Prince, A.-M. Engelbrecht (Stellenbosch; Cape Town, South Africa) (15')

## BREAST CANCER

Room B, 18:00-20:00  
Saturday, October 10

Chair Persons: K. Helou, A. Kovács

400. Surgical management of the breast after neoadjuvant chemotherapy. **R. Jakesz** (Vienna, Austria) (20')
501. Clinical relevance of a four-marker panel associated with breast cancer. **K. Helou**, E. Werner Rönnerman, A. Kovács, P. Karlsson, T.Z. Parris (Gothenburg, Sweden) (20')
541. Increased serum tumor necrosis factor receptor-associated factor 6 expression in patients with non-metastatic triple-negative breast cancer. **H. Engin**, C. Bilir, M. Can, S. Uygün İlikhan, D. Demirtaş, F. Kuzu, T. Bayraktaroğlu (Kozlu, Turkey) (20')
358. Incidence of previously diagnosed, other primary malignant tumors in breast cancer patients: A retrospective statistical evaluation in 2007-2014. **A. Kovács**, I. Várkonyi, T. Parris, E. Werner Rönnerman, K. Helou (Gothenburg, Sweden) (20')
459. Circadian rhythms and breast cancer: The role of per2 in doxorubicin-induced cell death. **M.I. Mitchell**, A.-M. Engelbrecht (Stellenbosch, South Africa) (20')
461. Let-7c inhibits estrogen-induced breast carcinogenesis via repression of self-renewal ability of breast cancer stem cells. **X. Sun**, D. Liu, Y. Zhang, N. Du, S. Qin, C. Xu, J. Liu, H. Wang, K. Chen, H. Ren (Xi'an; Wuhan, P.R. China) (20')



## MOLECULAR ONCOLOGY/PHARMACOLOGY/MELANOMA

Room C, 09:00-11:00  
Saturday, October 10

Chair Persons: X.D. Zhang, M. Libra

423. RIP1 kinase is an oncogenic driver in melanoma. X.Y. Liu, F. Lai, X.G. Yan, C.C. Jiang, S.T. Guo, C.Y. Wang, A. Croft, H.-Y. Tseng, J.S. Wilmott, R.A. Scolyer, L. Jin, **X.D. Zhang** (Newcastle; Sydney, Australia; Anhui; Shanxi, P.R. China) (20')
483. MMP-9 as a marker of response to treatment with B-Raf inhibitors in cutaneous melanoma. **R. Salemi**, S. Candido, J.A. McCubrey, F.M. Pezzino, G. Malaponte, M. Libra (Catania, Italy; Greenville, NC, USA) (20')
242. BILL<sup>CD8</sup> - A multivariable survival model based on detailed histopathological parameters of primary tumors in cutaneous melanoma patients. **P. Donizy**, P. Biecek, A. Halon, R. Matkowski (Wroclaw, Poland) (15')
480. Postoperative wound fluid stimulates *ex vivo* soft sarcoma re-growth. **F. De Nigris**, M. Libra, G. Colella, F. Fazioli (Naples; Catania, Italy) (15')
499. Understanding responses to targeted therapy and immunotherapy in melanoma: Rationale for combination strategies. **Z.A. Cooper**, A. Reuben, C. Spencer, J. Austin-Breneman, H. Jiang, P.-L. Chen, C. Haymaker, R.N. Amaria, M.T. Tetzlaff, K.T. Flaherty, L. Chin, K.C. Dwyer, J.A. Wargo (Houston, TX; Boston, MA, USA) (15')
549. SRC signalling in metastatic colorectal cancer. C. Naudin, C. Chevalier, G. Collin, C. Leroy, A. Sirvent, V. Simon, S. Descamps, C. Bénistant, **S. Roche** (Montpellier, France) (20')
548. Challenges in treatment of neurofibromatosis type 1. **D. Babovic-Vuksanovic**, D.R. Deyle (Rochester, MN, USA) (15')

## CLINICAL ONCOLOGY/SURGICAL ONCOLOGY

Room C, 11:30-13:30  
Saturday, October 10

Chair Persons: N.P. Murray, X.-C. Zhou

125. From clinical trial to clinical practice: The use of primary circulating prostate cells to detect prostate cancer at first biopsy. **N.P. Murray**, E. Reyes, N. Orellana, C. Fuentealba, O. Jacob (Santiago, Chile) (30')
154. Computed tomographic pelvimetry and clinical-pathological parameters in evaluation of the technical difficulties in performing open rectal surgery for mid-low rectal cancer. **X.-C. Zhou**, M. Su, K.-Q. Hu, Y.-F. Su, Y.-H. Ye, C.-Q. Huang, Z.-L. Yu, X.-Y. Li, H. Zhou, Y.-Z. Ni, Y. Jiang (Wenzhou, P.R. China) (30')
129. Prognostic impact of the number of lymph nodes evaluated in the survival of patients submitted to CRC surgery. **K.M. Ladeira**, S.F. Martins (Braga; Braga/Guimarães; Vila Real, Portugal) (20')
147. Splenectomy as part of cytoreduction for advanced ovarian cancer - From initial cytoreduction to surgery for quaternary relapse. N. Bacalbasa, **I. Balescu**, S. Dima, V. Brasoveanu, I. Popescu (Bucharest, Romania) (20')
225. Surgical outcomes for spinal meningioma over a period of 25 years. **M. Abematsu**, H. Tominaga, I. Kawamura, T. Yamamoto, K. Yone, S. Komiya (Kagoshima, Japan) (20')

## WORKSHOP ON PAEDIATRIC VIROLOGY

Room C, 15:30-17:30  
Saturday, October 10

Chair Persons: M. Theodoridou, A. Greenough, A. Kramvis

438. Defeating polio: Vaccine anniversary (1955-2015). **M. Theodoridou** (Athens, Greece) (20')
439. The impact of viral infections on the long-term outcomes of prematurely born infants. **A. Greenough**, S. Drysdale, S. Broughton, L. Bont (London, UK) (20')
440. The clinical implications of hepatitis B virus genotypes in Paediatrics. **A. Kramvis** (Johannesburg, South Africa) (20')
441. The challenge of modern biowarfare: ED preparedness for paediatric victims of the Ebola virus. **I. Christaki**, T. Beattie, P. Midgley (Edinburg, UK) (15')
442. Understanding the factors affecting human papillomavirus vaccination acceptance among adolescents. **I.N. Mammis**, G. Sourvinos, M. Theodoridou, D.A. Spandidos (Crete; Athens, Greece) (15')
443. HPV infections in children: Current surgical treatment of HPV lesions found in the oral cavity, oropharynx, larynx and nose cavity. **G. Kostagianni** (Athens, Greece) (10')
444. The clinical profile of infants with RSV bronchiolitis in PICU. **C. Koutsaftiki** (Athens, Greece) (10')
445. MMR vaccination and autism: An update. **M. Koutsaki** (Heraklion, Greece) (10')

## INFECTIOUS DISEASES

Room C, 18:00-20:00  
Saturday, October 10

Chair Persons: T.I. Michalak, A.J. Sinclair, R.M. Pascale

195. Molecularly evident but serologically silent hepadnavirus infection causes hepatocellular carcinoma in woodchuck model of hepatitis B. P.M. Mulrooney-Cousins, R. Chauhan, N.D. Churchill, **T.I. Michalak** (St. John's, Canada) (25')
182. Epstein Barr virus transcription factor Zta acts through distal regulatory elements to directly control cellular gene expression. S. Ramasubramanian, K. Osborn, R. Al-Mohammad, I.B.N. Perez-Fernandez, J. Zuo, N. Balan, A. Godfrey, H. Patel, G. Peters, M. Rowe, R.G. Jenner, **A.J. Sinclair** (Brighton; Birmingham; London, UK) (25')
137. Role of YAP signalling deregulation in the genetic susceptibility to hepatocarcinogenesis, and stemness and aggressivity of liver cancer. G. Latte, I. Demartis, I. Spissu, C. Cossu, L. Daino, M.A. Seddaiu, M.M. Simile, **R.M. Pascale** (Sassari, Italy) (25')
167. Sequence variations of full-length hepatitis B virus genomes in Chinese patients with HBsAg-negative hepatitis B infection. **F.-Y. Huang**, D.K.-H. Wong, W.-K. Seto, A.-Y. Zhang, C.-K. Lee, C.-K. Lin, J. Fung, C.-L. Lai, M.-F. Yuen (Hong Kong, P.R. China) (15')
315. Tumoral presence of cytomegalovirus in colorectal cancer is associated with post-operative blood carcinoembryonic antigen but not viral load levels in blood. **W.H. Teo**, H.-P. Chen, P.Y. Lai, J.C. Huang, Y.-J. Chan (Taipei, Taiwan, R.O.C.) (15')
332. Detection of human papillomavirus in the stool of colorectal cancer patients. **Yusra**, S. Nurbaya, D. Kristanti, A.T. Tedja, W. Ernajanti, Z. Adhim (Jakarta, Indonesia) (15')

## BRAIN TUMORS

Room D, 09:00-11:00  
Saturday, October 10

Chair Persons: M. Jhanwar-Uniyal, A. Adachi

410. Targeting glioblastoma and its stem cells using novel small molecule inhibitors of the mTOR pathway. **M. Jhanwar-Uniyal** (Valhalla, NY, USA) (25')
357. Brain tumour induced by heavy particle radiotherapy: A case report. **A. Adachi**, Y. Iwadate, S. Ikegami, M. Kambe, A. Hasegawa, T. Inaniwa, N. Saeki (Inohana; Anagawa, Japan) (20')
213. Glim2 regulates the proliferation of glioblastoma-initiating cells through the activation of the STAT3 signaling. **T. Kondo**, S. Kaneko (Sapporo; Kobe, Japan) (15')
313. Features of the interaction between stem cells and tumor cells in a C6 glioma model. **P. Mischenko**, I. Bryukhovetskiy, E. Tolok, S. Zaitcev, Y. Khotimchenko (Vladivostok, Russia) (15')
384. Clinical application of targeted next-generation sequencing for glioblastoma patients. M. Le Mercier, A.-L. Trépant, C. Maris, N. De Nève, O. Blanchard, **N. D'Haene**, I. Salmon (Brussels, Belgium) (15')
396. Upregulation of CSPG4/NG2 confers poor prognosis in patients with glioblastoma. **A.Y. Tsidulko**, G.M. Kazanskaya, D.V. Kostromskaya, S.V. Aidagulova, R.S. Kiselev, A.M. Volkov, V.V. Kobozev, A.S. Gaitan, T.Y. Prudnikova, A.L. Krivoschapkin, E.V. Grigorieva (Novosibirsk; Moscow, Russia) (15')
417. CXCR4, a pharmacological target in the treatment of glioblastoma. **C. Festuccia**, G.L. Gravina, P.J. Richardson (L'Aquila, Italy; Cambridge, UK) (15')

## THERAPEUTICS/BREAST CANCER

Room D, 11:30-13:30  
Saturday, October 10

Chair Persons: N. Telang, D.W. Felsner

117. Therapeutic efficacy of herbal extracts on a model for triple negative breast cancer. **N. Telang** (Montvale, NJ, USA) (30')
111. Oncogene addiction and metabolism. **D.W. Felsner** (Stanford, CA, USA) (30')
527. KISS1R signaling in triple negative breast cancer. C. Goertzen, M. Noonan, A. Blake, M. Dragan, A. Babwah, **M. Bhattacharya** (Ontario; London, Canada) (30')
340. Targeting IL13Ralpha2 activates STAT6-TP63 pathway to suppress breast cancer metastasis. **P. Papageorgis**, S. Ozturk, A.W. Lambert, C.M. Neophytou, A. Tzatsos, C.K. Wong, S. Thiagalingam, A. Constantinou (Nicosia, Cyprus; Boston, MA; Washington, DC, USA) (15')
497. Targeting MUC1-C oncoprotein in colorectal cancer. **R. Ahmad** (Riyadh, Saudi Arabia) (15')

## MOLECULAR ONCOLOGY

Room D, 15:30-17:30  
Saturday, October 10

Chair Persons: I. Di Liegro, K.M. Antoniou

326. Extracellular vesicles released from melanoma cells contain H1<sup>o</sup> mRNA-binding proteins, one of which is probably MYEF2. G. Schiera, C.M. Di Liegro, V. Puleo, O. Colletta, **I. Di Liegro** (Palermo, Italy) (20')
494. Retinoic acid-related orphan receptor alpha (ROR $\alpha$ ) expression in pulmonary fibrosis. E. Tsitoura, E. Bibaki, A. Koutsopoulos, H. Koutoulaki, E. Lagoudaki, E. Charalambous, N. Sifakas, G. Sourvinos, **K.M. Antoniou** (Heraklion, Greece) (20')
557. Hypercalcemia of malignancy: Pathophysiology and treatment. **F. Lumachi**, S.M.M. Basso (Padova; Pordenone, Italy) (20')
187. Medication reconciliation in oncology and monitoring of preventable drug interactions. **E. Tenti**, A. Schirone, A. Passardi, A.C. Gardini (Meldola, Italy) (15')
404. Changes in cancer cell glycosylation are a potential source for intratumour heterogeneity. A.V. Suhovskih, A.Y. Tsidulko, **E.V. Grigorieva** (Novosibirsk, Russia; Stockholm, Sweden) (15')
412. Characterisation of mesenchymal stem cells derived from human osteosarcoma: Their role in the bone tumor niche. **V. Trichet**, LR. Le Nail, P. Avril, F. Deschaseaux, D. Heymann, P. Rosset, G. De Pinieux (Nantes; Tours; Toulouse, France) (15')
522. The anti-obesity agent Orlistat downregulates the DNA repair enzyme O<sup>6</sup>-methylguanine-DNA methyltransferase. **G. Cioccoloni**, L. Bonmassar, E. Pagani, S. Caporali, M.P. Fuggetta, E. Bonmassar, S. D'Atri, A. Aquino (Rome, Italy) (15')

## MOLECULAR MEDICINE/ONCOLOGY

Room D, 18:00-20:00  
Saturday, October 10

Chair Persons: E. Isogai, E. Aydemir, E. Şimşek

343. Pathogenesis of leptospirosis: The role of leptospiral lipopolysaccharide. **E. Isogai**, Y. Guo, K. Kuroda, M. Masuda, J. Xu, R. Tomioka, T. Fukuda, K. Donai, S. Nakamura, H. Isogai (Sendai; Sapporo, Japan) (20')
408. Flavonoids as anti-cancer agents and their mechanism of action. **E. Aydemir** (Antalya, Turkey) (20')
275. Substance P: A trivet between cancer, angiogenesis and pain. **E. Şimşek** (Antalya, Turkey) (20')
307. Molecular analyses of the mouse brain exposed to chronic mild stress; the relation between depression and physiological dyshomeostasis. **K. Ikubo**, K. Yamanishi, N. Doe, M. Sumida, Y. Watanabe, M. Yoshida, W. Li, H. Okamura, H. Matsunaga, H. Yamanishi (Hyogo; Osaka, Japan) (20')
454. Possible pathogenetic effect of microRNA expression profiles in Merkel cell polyomavirus-positive non-small cell lung cancer. **I. Lasithiotaki**, K.M. Antoniou, E. Tsitoura, D.A. Spandidos, N.M. Sifakas, G. Sourvinos (Heraklion, Greece) (20')
132. Molecular targets of aspirin and cancer prevention. **J.B. Gunaje** (Brookings, SD, USA) (20')

## MOLECULAR ONCOLOGY/CANCER TREATMENT

Room E, 09:00-11:00  
Saturday, October 10

Chair Persons: J.G. Sinkovics, N. İmir

387. Extant eukaryotes revert to the immortalizing cell survival pathways of their primordial ancestors. **J.G. Sinkovics** (Tampa, FL, USA) (25')
348. The role of interferon regulatory factors, especially IRF-1 and IRF-2, in the regulation of oncogenesis. **N. İmir** (Antalya, Turkey) (25')
525. Observation of breast cancer metastasis and symbiotic bacteria in stomach mucosa immersed in aqueous solution by atmospheric scanning electron microscopy (ASEM). **C. Sato**, M. Sato, T. Ebihara, M. Kawata, N. Memtily (Tsukuba, Japan) (20')
535. Telomerase and telomeres as targeted therapies. **Z.G. Dikmen** (Ankara, Turkey) (20')
120. The value of androgen receptor and CD10 expression in cutaneous basal cell carcinoma and trichoepithelioma. **H.M. Astarci, G. Ates Gurbuz**, D. Sengul, S. Hucumenoglu, U. Kocer, H. Ustun (Bolu; Ankara; Giresun; Kars, Turkey) (15')
317. Herbal extracts in palliative care: A new challenge and potential strategy for the treatment of advanced cancer. **R. Pu, W. Yin, L. Zhang, Y. Tian, X. Li** (Chengdu, P.R. China) (15')

## MOLECULAR MEDICINE/ONCOLOGY

Room E, 11:30-13:30  
Saturday, October 10

Chair Persons: S. Sifakis, L.E.M. Cardoso, B. Baron

414. Non-invasive prenatal diagnosis of Down syndrome and the use of cell-free fetal DNA testing: Current knowledge and novel insights. **S. Sifakis** (Heraklion, Greece) (20')
354. Nutritional supplementation with arginine or glutamine attenuates radiation-induced genitourinary injuries in an animal model of pelvic radiotherapy. **L.E.M. Cardoso** (Rio de Janeiro, Brazil) (20')
337. Investigating the role of HSP lysine methylation in cancer. **B. Baron**, T. Kitagawa, Y. Kuramitsu (Msida, Malta; Yamaguchi, Japan) (20')
355. Novel approaches to rational design of anti-cancer drugs. **N.A. Barlev**, O. Fedorova, A. Daks, O. Shuvalov (St. Petersburg, Russia) (15')
310. Tumor-induced Neutrophil Extracellular Traps (NETs) occlude peripheral vessels and compromise organ function in mice with cancer. **J. Cedervall**, Y. Zhang, H. Huang, L. Zhang, J. Femel, A. Dimberg, A.-K. Olsson (Uppsala, Sweden) (15')
206. Synergistic effects of crocetin and cisplatin on KYSE-150 cells. **S. Li**, Y. Zhou, X.-Y. Shen, T. Luo, H.-Q. Wang (Guangzhou, P.R. China) (15')
536. The genetic basis of cancer. **E. Mosaad** (Assiut, Egypt) (15')

## MOLECULAR AND CLINICAL ONCOLOGY

Room E, 15:30-17:30  
Saturday, October 10

Chair Persons: M. Christofidou-Solomidou, T. Nakamura, S.P.R. Shenoy

434. From bench to bedside: Developing a botanical therapy for mitigating the side effects of radiotherapy for thoracic malignancies. **M. Christofidou-Solomidou**, C.C. Solomides, C. Koumenis (Philadelphia, PA, USA) (20')
253. Kampo medicine, *Shosaihoto*, inhibits tumor progression induced by IL-1 $\beta$  recruiting macrophages in transgenic mice. **T. Nakamura** (Kurashiki, Japan) (20')
526. Unforeseen role of GSK3 $\alpha$  and GSK3 $\beta$  isoforms in prostate tumor growth and metastasis. F. Gao, A. Al-Azayzih, **S.P.R. Shenoy** (Augusta, GA, USA) (20')
141. Anticancer effects of glucan combined with organic selenium derivative. **V. Vetvicka**, M.F. Pinatto-Botelho, A.A. Dos Santos, C.A.F. De Oliveira (Louisville, KY, USA; São Paulo; Lencóis Paulista, Brazil) (15')
140. Statins in cancer: A review of the literature and future directions. **A.K. Altwaairgi** (Riyadh, Saudi Arabia) (15')
188. Glucosylceramide synthase blockade sensitizes head and neck cancer cells to cisplatin. J.Y. Park, E.H. Kim, H.J. Jang, J.W. Kim, Y. Park, **J.-L. Roh** (Seoul, Republic of Korea) (15')
342. The establishment of a molecular imaging model of retroperitoneal lymph node metastasis in ovarian cancer. **Y. Kang**, T. Pu, L. Xiong, M. Zhang, Q. Cai, S. Hong, G. Li, C. Xu (Shanghai, P.R. China) (15')

## MOLECULAR MEDICINE/MOLECULAR ONCOLOGY

Room E, 18:00-20:00  
Saturday, October 10

Chair Persons: L.M. Junie, W.J. Malaisse

130. Molecular epidemiology of epidemic and pandemic MRSA clone circulation in Romania. **L.M. Junie**, L.M. Simon, S. Pandrea (Cluj Napoca, Romania) (25')
145. Pyruvate kinase activity in insulin-producing cells. **W.J. Malaisse**, E. Kaçin, Y. Zhang, A. Sener (Brussels, Belgium) (20')
248. Knockdown of HMGN2 increases *Klebsiella pneumoniae* internalization into respiratory epithelial cells through regulating  $\alpha$ 5 $\beta$ 1 integrin. **X. Wang**, J. Li, S. Chen, X. Shen, X. Yang, Y. Teng, L. Deng, J. Chen, Y. Wang, X. Wang, N. Huang (Chengdu, P.R. China) (20')
381. Prognostic and predictive immunohistochemical markers for recurrence in DCIS (intraductal carcinoma) of the breast: Are we in the era of molecular phenotypes of DCIS? G.-M. Makris, M.-J. Battista, K. Petraki, T.N. Sergentanis, D. Bafaloukos, **N. Poulakaki** (Athens, Greece; Mainz, Germany) (25')
532. Specific antiproliferative effect of 17-alpha-19-nortestosterone and its analogue in HeLa cells. **R. Minorics**, N. Bózsity, A. Gyovai, E. Mernyák, J. Wölfling, G. Schneider, I. Zupkó (Szeged, Hungary) (15')
550. Immunoproteasome, a novel target for cancer therapy. **G. Pissas** (Larissa, Greece) (15')

POSTERS (Poster viewing during the entire congress)

119. Xenohybridomas as sources of animal monoclonal antibodies for some important diagnostic antigens. **V. Sologub**, I. Koromyslova, L. Dudnikov, A. Biryukov, S. Severin (Moscow, Russia)
122. Exploring the mechanism for cancer associated fibroblasts recruitment and the potential therapeutic value in esophageal squamous cell carcinoma. **J. Qi**, L. Zhang, X. Guan (Hong Kong, P.R. China)
131. Autophagy can make MDR-positive lung cancer cell lines more prone to cell death overcoming drug resistance. **A.P. Spongini**, F. Platini, D. Rondonotti, S. Ambrosio, R. Pérez-Tomás (Novara, Italy; Barcelona, Spain)
136. Identification and characterization of oncogene GMNN in hepatocellular carcinoma. **S. Fang**, X. Yang, X.-Y. Guan (Hong Kong, P.R. China)
138. The association of *PDRG1* expression with clinicopathological significance and prognosis in hepatocellular carcinoma. **X. Yang**, X.-Y. Guan (Hong Kong, P.R. China)
139. CAB39 regulates the MEK/ERK signaling pathway and promotes cell proliferation, invasiveness and metastasis in hepatocellular carcinoma. **L.-X. Jiang**, X.-Y. Guan (Hong Kong, P.R. China)
143. Angiopoietin-like protein 1 functions as a tumor suppressor in hepatocellular carcinoma. **Q. Yan**, L. Jiang, X. Guan (Hong Kong, P.R. China)
152. Reduced expression of *PSCA*, a novel tumor suppressor gene, is regulated by transcription factor SOX5 in esophageal squamous cell carcinoma. **L.-Y. Zhang**, L. Fu, X.-Y. Guan (Hong Kong, P.R. China)
166. The stabilisation of Snail by Cten increases tumourigenicity in the colon. **H. Thorpe**, M. Akhlaq, A. Asiri, M. Ilyas (Nottingham, UK)
169. Delphinidin induces cytotoxicity and potentiates cytotoxic effect in combination with arsenite in an acute promyelocytic leukemia cell line, NB4. **B. Yuan**, S. Okusumi, Y. Yoshino, S. Tanaka, T. Hirano, H. Toyoda, H. Hayashi, N. Takagi (Tokyo, Japan)
171. DNMT3B gene variants in relation with colorectal cancer risk in the Kazakhstan population. **A.V. Perfilyeva**, S.E. Abdikerim, G.S. Zhunussova, O.A. Iksan, K.B. Jantayeva, E.M. Khussainova, G.A. Afonon, B.O. Beckmanov, L.B. Djansugurova (Almaty, Republic of Kazakhstan)
173. Identification and characterization of a novel protein family as a new component of TRPM8 regulation and its implication in cancer. **D. Gkika**, L. Lemonnier, G. Shapovalov, D. Gordienko, C. Poux, M. Bernardini, A. Bokhobza, G. Bidaux, C. Degerny, B. Guarmit, M. Benahmed, Y. De Launoit, R.J. Bindels, A.F. Pla, N. Prevarskaya (Lille; Nice, France; Torino, Italy; Nijmegen, The Netherlands)
174. TRPM8 is a novel Rap1 GTPase inhibitor that controls  $\beta$ 1 integrin-mediated endothelial cell adhesion and migration. **D. Gkika**, T. Genova, M. Bernardini, E. Richard, M. Scianna, L. Lemonnier, A. Bokhobza, L.M. Luca, C. Camillo, D. Valdembri, G. Serini, N. Prevarskaya, A.F. Pla (Lille, France; Torino, Italy)
176. Effects of ANXA1 on the proliferation, migration and invasion of esophageal squamous cell line Eca109 cells. **G. Han**, K. Lu, J. Huang, Y. Ye, L. Zhang, J. Ye (Taizhou, P.R. China)
178. Molecular identification of non-tuberculous mycobacteria in a routine laboratory. **P. Spatharaki**, F. Kontos, D. Mavromanolakis, Z. Gitti, D.A. Spandidos (Heraklion; Athens, Greece)
179. Evaluation of genotype MTBDRplus assay for molecular detection of rifampin and isoniazid resistance in *Mycobacterium tuberculosis complex* strains and clinical samples. **P. Spatharaki**, F. Kontos, D. Mavromanolakis, Z. Gitti, D.A. Spandidos (Heraklion; Athens, Greece)

180. Evaluation of Genotype MTBC assay for differentiation of clinical Mycobacterium complex isolates. **P. Spatharaki**, F. Kontos, D. Mavromanolakis, Z. Gitti, D.A. Spandidos (Heraklion; Athens, Greece)
184. Association between the expression of various cancer-related proteins, including FAK, and mode of invasion in oral squamous cell carcinoma. **K. Yoshizawa**, A. Kato, T. Tsutsui, A. Hotta, Y. Saida, A. Kosaka, H. Ikawa, R. Iguchi, M. Higuchi, A. Moroi, K. Ueki (Chuo; Kanazawa, Japan)
193. Inhibitory effect of PDGF-BB and serum-stimulated responses in vascular smooth muscle cell proliferation by hinokitiol via up-regulation of p21 and p53. **J.-R. Sheu**, C.-Y. Hsieh (Taipei, Taiwan, R.O.C.)
205. Assessment of *Her-2/neu* gene amplification and expression as a biomarker for radiotherapy and hormone-treated breast cancer patients in Upper Egypt. M. Essmat, M. AbdelWanis, **E. Mosad**, T. El-Maghraby, A. Othman (Cairo; Assiut, Egypt)
211. Immune gene set enrichment in women with non-small cell lung cancer. **N. Cárdenas**, J. Araujo, Z. Morante, A. Aguilar, H. Gomez, J. Pinto (Lima, Peru)
212. Prognostic influence of bcl-2 expression among women with breast cancer in Libya. **E. Ermiah** (Sabratha, Libya)
216. Epithelial-myoepithelial carcinoma (EMEC) of the parotid gland. **J.K. Fortson**, R. Su, G.E. Lawrence, V.G. Patel (Atlanta, GA, USA; Spanish Town, Jamaica)
217. Malignant neoplasm of the sphenoidal sinus. **J.K. Fortson**, R. Su, G.E. Lawrence, V.G. Patel (Atlanta, GA, USA; Spanish Town, Jamaica)
219. Changes in oxidative stress status after the administration of doxorubicin-loaded nanocarriers. **M. Fojtu**, J. Gumulec, M. Sztalmachova, M. Raudenska, T. Stracina, M. Novakova, R. Kizek, V. Adam, M. Hlavacova, H. Paulova, M. Masarik (Brno, Czech Republic)
220. The mechanisms of resistance in a prostate cancer model with long-term exposure to zinc. **M. Holubova**, J. Gumulec, M. Raudenska, M. Sztalmachova, M. Novakova, R. Kizek, M. Masarik (Brno, Czech Republic)
221. Expression profiling of selected miRNAs in connection with head and neck squamous cell carcinoma. **K. Hudcova**, M. Raudenska, H. Polanska, J. Gumulec, M. Fojtu, M. Sztalmachova, J. Balvan, H. Binková, Z. Horakova, R. Kostrica, M. Feith, R. Kizek, M. Masarik (Brno, Czech Republic)
222. Characterization of cell subpopulations in primary cultures derived from head and neck squamous cell carcinoma. **M. Sztalmachova**, H. Polanska, J. Gumulec, M. Raudenska, J. Balvan, H. Binková, Z. Horakova, R. Kostrica, M. Feith, M. Masarik (Brno, Czech Republic)
223. Elucidation of Pirh2 interactome within the context of cancer-associated pathways. **A. Daks**, O. Fedorova, A. Petukhov, O. Shuvalov, E. Vasileva, N. Barlev (St. Petersburg, Russia)
227. IL-6 induced by cisplatin and camptothecin contributes to multidrug resistance by activating ATM/NF- $\kappa$ B pathway. H.Q. Yan, X.B. Huang, S.Z. Ke, Y.H. Zhang, Y.N. Wang, F.G. Gao, **Q. Li** (Xiamen; Shanghai, P.R. China)
228. Comparison among MDM2 isoforms in cancer cells with regard to their oncogenic properties. **O. Shuvalov**, A. Petukhov, O. Fedorova, A. Daks, E. Vasileva, N. Barlev (St. Petersburg, Russia)
230. Involvement of connective tissue growth factor in fibrocyte proliferation and differentiation in tuberculosis. **C.-H. Lin**, H.-S. Lee, B.-C. Chen, C.-L. Chung (Taipei, Taiwan, R.O.C.)
233. Inhibition of autophagic flux by ROS promotes apoptosis during severe ER stress. X. Xiang, Y. Wu, X. Yan, Y. Xue, **L. Sun** (Changchun, P.R. China)
235. Aspirin kills and sensitizes melanoma cells to TRAIL through mitochondrial calcium homeostasis disruption. **I. Fujikawa**, M. Suzuki-Karasaki, C. Nakagawa, M. Uchida, T. Ochiai, Y. Suzuki-Karasaki (Tokyo, Japan)



237. Biological evaluation of novel small-molecule activators of p53. **O. Fedorova**, A. Daks, A. Petukhov, O. Shuvalov, E. Vasileva, N. Barlev (St. Petersburg, Russia)
249. Secondary mutations in the KIT gene and mutation analysis of the BRAF gene in patients with gastrointestinal stromal tumors and implications of their assessment. **A. Kalfusova**, I. Hilska, P. Babu, Z. Linke, R. Kodet (Prague, Czech Republic)
251. XRCC2 4234G/C genetic polymorphism and risk of breast cancer in Polish women. B. Smolarz, **H. Romanowicz** (Lodz, Poland)
254. Concanavalin A induces autophagy-dependent cellular senescence in hepatocellular carcinoma cells. **C.-H. Chen**, C.-P. Chang (Tainan, Taiwan, R.O.C)
260. External Qi of Qigong induces apoptosis and inhibits EGF/EGFR and TGF $\beta$ /Smad signaling in non-small cell lung carcinoma cells. X. Yan, H. Shen, H. Jiang, D. Hu, J. Wang, **X. Wu** (Chongqing, P.R. China; New York, NY; Boston, MA, USA)
268. The role of methyltransferase Set7/9 interaction with RNA-binding protein Sam68. **E. Vasileva**, O. Fedorova, O. Shuvalov, A. Daks, A. Petukhov, N. Barlev (St. Petersburg, Russia)
272. Adjuvant oral 5-fluorouracil for cervical cancer. **K. Yamamoto** (Sakai, Japan)
274. Resveratrol protects astrocytes against traumatic brain injury through inhibiting apoptotic and autophagic cell death. C.-J. Lin, **C.-M. Shih** (Taipei, Taiwan, R.O.C.)
278. Artesunate alters cellular mechanical properties to resist tumors. **R. Shi**, X. Huang, S. Lian, B. Song, C. Cheng, J. Liu, B. Yang, L. Zhang, X. Cheng (Taiyuan; Guangzhou, P.R. China)
279. Mammalian target of rapamycin complex 2 (mTORC2) regulates LPS-induced expression of IL-12 and IL-23 in human dendritic cells. W.-C. Wei, W.-C. Yang, L.-F. Shyur, J.-H. Sheu, **N.-S. Yang** (Taipei, Taiwan, R.O.C.)
285. Role of calcium in TRAIL resistance in malignant tumor cells: Implications of TRPV1. **N. Takata**, M. Suzuki-Karasaki, E. Osaka, Y. Yoshida, T. Ochiai, Y. Tokuhashi, Y. Suzuki-Karasaki (Tokyo, Japan)
287. Merkel cell polyomavirus miRNA modulates the expression of cellular transcripts associated with tumorigenesis. **P. Akhbari**, J.R. Boyne (Bradford, UK)
288. Breast cancer or not - a retrospective GATA3 immunohistochemical study. A. Kovacs, T.Z. Parris, **E. Werner Rönnerman**, K. Helou, S. Hajizadeh (Gothenburg, Sweden)
290. Different forms of serum gelatinases in human intracranial neoplasms. **S. Ricci**, D. Bruzzese, E. Guadagno, C. Peca, F.G. Sgulò, M. Del Basso De Caro, F. Maiuri, A. Di Carlo (Naples; Rome, Italy)
294. Nicotinamide sensitizes human breast cancer cells to the cytotoxic effects of radiation and cisplatin. **G. Domínguez-Gómez**, A. Chávez-Blanco, J. Díaz-Chávez, P. Damián-Matsumura, L.E. Gómez-Quiroz, A. Dueñas-González (Mexico)
297. The G2-micronucleus assay for assessing the *in vitro* chromosomal radiosensitivity in healthy *BRCA1* mutation carriers. A. Baert, J. Depuydt, B. Poppe, T. van Maerken, F. Malfait, T. van Damme, S. De Nobele, K. De Leeneer, K. Claes, **A. Vral** (Ghent, Belgium)
298. Temporal shifts in cause of death for oral cavity cancer patients: Oral cancer versus other chronic disease. A. Auluck, R. Woods, S. Lear, G. Hislop, **M. Rosin** (Burnaby; Vancouver, Canada)
300. Combined treatment of cancer cells with the new anti-neoplastic agents erufosine and doxorubicin. V. Uzunova, A. Georgieva, S. Apostolova, I. Ugrinova, R. Toshkova, M.R. Berger, **R. Tzoneva** (Sofia, Bulgaria; Heidelberg, Germany)

304. Luteolin inhibits the recruitment of monocytes through restraining M2 macrophage polarization. H.-J. Choi, S.-C. Moon, H.-J. Choi, T.-W. Chung, **K.-T. Ha** (Yongsan, Republic of Korea)
305. *Myristica Fragrans* Hoult. inhibits cancer metabolism through suppressing LDHA enzyme activity. E.-Y. Kim, E.-J. Lee, T.-W. Chung, **K.-T. Ha** (Yongsan, Republic of Korea)
306. Characterization of the role of EBV microRNAs in nasopharyngeal carcinoma. **J. Chen**, A.M. Go Wong, X.-Y. Guan (Pokfulam, Hong Kong; Guangzhou, P.R. China)
312. (-)-Gomisin L1 isolated from *Schisandra Chinensis* fruit induces G2/M arrest and apoptosis in human ovarian cancer cells. **Y.-H. Ko**, J.-H. Ahn, D.-S. Jang, J.-H. Choi (Seoul, Republic of Korea)
316. Pharmacokinetics and drug release of a cisplatin-mifepristone liposomal system for cancer treatment. **K.D. Ocaña-Arakachi**, F. Ledezma, J. Martínez, L.A. Medina, P. Garcia-Lopez (México)
319. Study of variants in cancer-related genes of South African and African populations. G.A. Milner, L. Jansen van Rensburg, **F. Joubert** (Pretoria, South Africa)
320. *In vitro* and *ex vivo* evaluation of *in silico*-designed estradiol analogues as potential anticancer agents. L. Repsold, T. Mqoco, S. Nkandeu, J. Theron, A. Stander, X. Stander, M. Visagie, F. Joubert, L. Lafanechère, R. Prudent, K. Sippel, R. McKenna, **A. Joubert** (Pretoria, South Africa; Grenoble, France; Houston, TX; Miami, FL, USA)
323. Role of periostin in pancreatic cancer progression. Y. Liu, **F. Li**, L. Xing, F. Gao, Q. Zhao, L. Du (Shanghai, P.R. China)
325. Synergism associated with temozolomide and mifepristone in a preclinical model of glioma. **M. Llaguno-Munive**, J. Serrano, M. Romero-Piña, L.A. Medina, P. García-Lopez (México)
327. H1<sup>o</sup> mRNA-containing complexes in rat brain cells. C.M. Di Liegro, A. Di Gregorio, G. Schiera, **I. Di Liegro** (Palermo, Italy)
329. Amino acids closely related to sarcosine metabolism and their effects on prostatic cell lines represented by normal, malignant and metastatic prostatic cell lines. Z. Heger, N. Cernei, J. Gumulec, **T. Eckschlager**, O. Zitka, V. Adam, R. Kizek (Brno; Prague, Czech Republic)
346. Immunohistochemical detection of biomarkers of intestinal metaplasia associated with *Helicobacter pylori* infection in children and young adults. **J.S. Park**, T.-U. Huh, J.Y. Cho, J.-S. Jun, J.-H. Park, J.-S. Yeom, J.-H. Seo, J.-Y. Lim, C.-H. Park, H.-O. Woo, H.-S. Youn, G.-H. Ko, H.-L. Kang, S.-C. Baik, W.-K. Lee, M.-J. Cho, K.-H. Rhee (Jinju, Republic of Korea)
349. oxLDL enhances the epithelial-mesenchymal transition and invasion process in prostate cancer cell lines. N. Gutiérrez, E. Fernandez, I. González-Chavarría, R. Cerro, F. Sandoval, **J.R. Toledo** (Concepción, Chile)
350. Activation of lectin-like oxidized low density lipoprotein receptor-1 promotes tumor angiogenesis in human prostate cancer cells. **I. González-Chavarría**, R. Cerro, E. Fernandez, F. Sandoval, N. Gutiérrez, J.R. Toledo (Concepción, Chile)
352. Establishment and initial characterization of the new human ovarian carcinoma cell line OVPA8. K.A. Kujawa, **P.A. Tudrej**, M. Olbryt, B. Nikiel, E. Zembala-Nożyńska, A.J. Cortez, K.M. Lisowska (Gliwice, Poland)
362. Identification of differentially expressed non-coding RNAs in 5-fluorouracil-resistant colon cancer cells. **H. Lee**, C. Kim, E.K. Lee (Seoul, Republic of Korea)
364. The impact of SFRP2 and MFAP5 proteins on ovarian cancer cell proliferation and migration rate. **A.J. Cortez**, P.A. Tudrej, K.A. Kujawa, U. Kruszczyk, K.M. Lisowska (Gliwice, Poland)
365. qPCR and immunohistochemical validation of CLASP1, FN1, MFAP5 and POSTN as prognostic markers in ovarian cancer. **K.A. Kujawa**, E. Zembala-Nożyńska, S. Student, A.J. Cortez, P.A. Tudrej, J. Kupryjańczyk, K.M. Lisowska (Gliwice; Warsaw, Poland)

368. Survivin may be a new target for effective treatment of CD133<sup>+</sup> colon cancer. W.L. Li, M.-R. Lee, E. Choi, **M.-Y. Cho** (Wonju, Republic of Korea)
371. Biological activity of the aqueous extract of passion fruit (*Passiflora edulis*) *in vitro* in cell lines of colon cancer. **S. Arango**, M.E. Maldonado, V. Ramirez, J. Aguillon (Medellin; Armenia, Colombia)
376. Role of purinergic signaling in the cross-talk between vascular endothelial and cancer cells. **S. Bianco**, E. Vallariello, A. Fiorio Pla, L. Munaron (Torino, Italy)
389. Differential expression of claudin-1 between well- to moderately-differentiated and poorly-differentiated gastric adenocarcinoma. **Y. Tokuhara**, T. Morinishi, T. Matsunaga, H. Ohsaki, Y. Kushida, R. Haba, E. Hirakawa (Kagawa; Osaka; Ehime, Japan)
394. Identification of novel regulators governing mitochondrial homeostasis in human liver cancer. **H. Tak**, J. Kim, E.K. Lee (Seoul, Republic of Korea)
395. Differential mucosal expression of claudin-1 is a prognostic factor in gastric cancer. **E. Hirakawa**, Y. Tokuhara, T. Morinishi, H. Ohsaki, E. Uemura, Y. Miki, T. Matsunaga, Y. Kushida, R. Haba (Kagawa; Ehime; Kochi, Japan)
397. Exploratory laparotomy for the resection of an ovarian teratoma that caused acute autoimmune thrombocytopenia in a female patient: A rare entity. **G.I. Panagiotakis**, A. Andreou, M. Velegraki, M. Chatziioannou, M. Tzardi, C. Pontikoglou, G.E. Chalkiadakis (Heraklion, Greece)
398. Laparoscopic repair of perforated peptic ulcer. A. Andreou, **G.I. Panagiotakis**, G.E. Chalkiadakis (Heraklion, Greece)
401. Spiritual well-being may reduce the negative impact of cancer symptoms on the quality of life and the desire for hastened death in terminally ill cancer patients. Y.-C. Wang, **C.-C. Lin** (Taipei, Taiwan, R.O.C.)
402. Prostate cancer angiogenesis: Differential sensitivity to current anti-angiogenic drugs and transient receptor potential (TRP) channels as novel therapeutic targets. **M. Bernardini**, A. Brossa, T. Genova, G. Grolez, A. Villers, X. Leroy, N. Prevarskaya, B. Bussolati, A. Fiorio Pla, D. Gkika (Lille, France; Torino, Italy)
407. Urinary biomarkers for colorectal cancer (CRC): The state of the art. **P.M. Angeletti**, A. Lattanzi, F. D'Aloisio, M. Castellucci, E. Altobelli (L'Aquila; Ancona, Italy)
413. The molecular recognition between cerebral cavernous malformation 2 and mitogen-activated protein kinase kinase kinase 3. **X. Wang**, Y. Hou, K. Deng, Y. Zhang, D.-C. Wang, J. Ding (Beijing; Hubei, P.R. China)
418. Blockade of the SDF-1/CXCR4 axis is additive/synergistic with radiotherapy and/or temozolomide treatment both *in vitro* and *in vivo* in preclinical models of glioblastoma. G.L. Gravina, A. Mancini, A. Colapietro, L. Scarsella, A. Jitariuc, S. Delle Monache, E. Di Cesare, P.J. Richardson, L. Patient, S. Burbidge, **C. Festuccia** (L'Aquila, Italy; Cambridge, UK)
419. The brain-penetrating CXCR4 antagonist PRX177 and anti-angiogenic agents combine synergistically to inhibit progression of glioblastoma. G.L. Gravina, A. Mancini, A. Colapietro, A. Jitariuc, S. Delle Monache, A. Angelucci, P.J. Richardson, L. Patient, S. Burbidge, **C. Festuccia** (L'Aquila, Italy; Cambridge, UK)
426. LncRNA-32 maintains a constant level of c-Myc. **M. Wu** (Hefei, P.R. China)
427. Inovotion assays for drug discovery. E. Dosda, X. Rousset, R. Prudent, R. Iratni, I. Mikaelian, L. Lafanechère, M. Billaud, **J. Viallet** (Grenoble; Lyon, France; Al Alain, United Arab Emirates)
432. Does RBFOX1 work in epilepsy? **M. Wen**, Y. Yan, N. Yan, X. Chen, S.Y. Liu, Z. Feng (Chongqing; Xi'an; Guiyang, P.R. China)
433. Inflammatory molecules in the serum of febrile patients: Can they be used for identifying pathogen species? K.-T. Liu, Y.-H. Liu, C.-Y. Lin, P.-L. Kuo, **M.-C. Yen** (Kaohsiung, Taiwan, R.O.C.)

435. Molecular diagnosis of bleeding disorders. **G. Soufla**, E. Melissari (Athens, Greece)
437. Toll-like receptor 2 gene polymorphisms in Korean women with human papillomavirus-related cervical neoplasia. **J.H. Kim**, E.Y. Ki, S.J. Lee, K.H. Lee, C.J. Kim, S.Y. Hur, T.C. Park, T.G. Kim, J.S. Park (Seoul, Republic of Korea)
446. Ocular viral infections in neonates and children. **D.M. Portaliou** (Heraklion, Greece)
447. Merkel cell polyomavirus (MCPyV): A novel emerging virus of infancy and childhood. **G. Sourvinos**, I.N. Mamas, D.A. Spandidos (Crete, Greece)
448. Management of infants with severe bronchiolitis who were admitted to two PICUs. **C. Koutsaftiki**, A. Tsialla, G. Sideri, A. Bampanelou, I. Papadatos, L. Sianidou (Athens, Greece)
449. Varicella cases in immunized children attending kindergarten. **C. Koutsaftiki**, O. Giannouli, M. Vasilopoulou, A. Tsialla, A. Voyatzi, L. Sianidou (Athens, Greece)
450. BI(G)MED in some hematological malignancies. **G. Glady** (Colmar, France)
451. Correlation between the clinical course and the immunophenotypic profile of T-cytotoxic lymphocytes in children with infectious mononucleosis. **P. Panagopoulou**, A. Fleva, E. Papadopoulou-Alataki, A. Pavlitou-Tsionsi, M. Emporiadou-Petikopoulou (Thessaloniki, Greece)
452. Determination of the frequency of STDs using the PCR technique. **M.L. Vică**, L.M. Junie, H.V. Matei (Cluj-Napoca, Romania)
453. The association of HLA class II alleles with hepatitis B in a Romanian population sample. **H.V. Matei**, C. Siserman, M.L. Vică (Cluj-Napoca, Romania)
457. Search for novel MALT1 inhibitors using ABC-DLBCL and GCB-DLBCL cell lines. **Y.H. Son**, C.H. Park, S.U. Choi (Daejeon, Republic of Korea)
458. Identification of a novel inhibitor of mutant IDH1 through high-throughput screening using clinical compound library. **C.H. Park**, C.H. Kang, S. Ahn, S.U. Choi, H.G. Jeong, M. Yoo (Daejeon, Republic of Korea)
464. Capicua as a negative regulator of the pathogenesis of hepatocellular carcinoma. **E. Kim**, Y. Lee (Pohang, Republic of Korea)
466. Chronic stress increases global DNA methylation in an experimental carcinogenesis model. **B. Venegas**, N. Huard, W. Donoso, L.A. Salazar (Talca; Valparaíso; Temuco, Chile)
470. Identification of mitotic blocker by phenotypic screening using a clinical compound library. **S.U. Choi**, C.H. Park, Y.-H. Son (Daejeon, Republic of Korea)
484. Analysis of PIK3CA mutations in cutaneous melanoma patients with occupational sun exposure. **A. Marconi**, M. Libra, R. Salemi, V. Rapisarda, S. Candido, A. Scalisi, C. Fenga (Catania; Messina, Italy)
485. S100A8/9 (calprotectin) is downregulated by biological therapy in psoriasis. **E. Skarmoutsou**, C. Trovato, M. Granata, G.A. Rossi, P. Gangemi, V. Longo, M. Pettinato, F. D'Amico, M.C. Mazzarino (Catania, Italy)
486. Studies in an animal model of post-stroke depression and treatment with antipsychotic aripiprazole. Y.R. Kim, Y.J. Yun, J.U. Baek, H.K. Shin, **B.T. Choi** (Yongsan, Republic of Korea)
487. Anti-neuroinflammatory effects of probucol in LPS-induced BV2 microglial cells and focal cerebral ischemia in mice. Y.S. Jung, Y.J. Yun, J.U. Baek, B.T. Choi, **H.K. Shin** (Yongsan, Republic of Korea)
489. The effects of flavonoids and phenolic compounds in propolis on the whole genome expression of MCF-7 and MCF-10A cells lines. **M.F. Seyhan**, A. Diren, H. Yilmaz-Aydoğan, O. Ozturk (Istanbul, Turkey)

492. The evolution of the IgH/Myc stem cell fusion oncoprotein I. **J.G. Sinkovics**, J.C. Horvath (Tampa, FL; New Brunswick, NJ, USA)
493. The evolution of the IgH/Myc stem cell fusion oncoprotein II. **J.G. Sinkovics**, J.C. Horvath (Tampa, FL; New Brunswick, NJ, USA)
500. Association between genotypes of the steroid metabolism gene CYP17 and the Forsen psychological risk inventory in breast cancer patients. **R. Korhonen**, A. Hirvonen, T. Selander, P. Ollonen, M. Eskelinen (Kuopio; Helsinki, Finland)
503. A validated THALAMOSS cellular biobank for  $\beta$ -thalassemia. L.C. Cosenza, L. Breda, G. Breveglieri, C. Zuccato, A. Finotti, I. Lampronti, F. Chiavilli, M.R. Gamberini, S. Satta, L. Moi, S. Rivella, **R. Gambari**, N. Bianchi (Ferrara; Rovigo; Cagliari, Italy; New York, NY, USA)
504. SPR-based non-invasive prenatal testing for fetal sex determination. G. Breveglieri, L.C. Cosenza, P. Pellegatti, G. Guerra, F. Salvatori, C. Gemmo, A. Finotti, **R. Gambari**, M. Borgatti (Ferrara, Italy)
505. Phloridzin derivatives inhibiting proinflammatory cytokine expression in human cystic fibrosis IB3-1 cells. I. Lampronti, R. Milani, G. Montagner, A. Marcellini, A. Baldisserotto, S. Manfredini, **R. Gambari** (Ferrara, Italy)
507. Digital microfluidic devices for isothermal circular strand displacement polymerization of microRNAs. M.C. Giuffrida, L.M. Zanolì, R. D'Agata, **A. Finotti**, J. Gasparello, M. Borgatti, R. Gambari, G. Spoto (Catania; Ferrara; Rome, Italy)
509. Induction of apoptosis of human glioma cell lines: Effects of combined treatment with corilagin and temozolomide. R. Milani, I. Lampronti, **E. Fabbri**, E. Brognara, N. Bianchi, A. Finotti, C.-H. Chui, M. Borgatti, R. Gambari (Ferrara, Italy; Hong Kong, P.R. China)
530. HPV co-infection in ophthalmic pterygium and cervix uteri: Clinical implications. E.T. Detorakis, **S. Derdas**, G. Sourvinos, D.A. Spandidos (Heraklion, Greece)
533. D-Secoestrone-triazol: A new secoestrone derivative with antiproliferative and antimigration effects in cervical cancer cells. **N. Bózsity**, R. Minorics, E. Mernyák, J. Szabó, G. Schneider, J. Wölfling, H.-C. Wang, C.-C. Wu, I. Zupkó (Szeged, Hungary; Kaohsiung, Taiwan, R.O.C.)
534. Antiproliferative properties of A-ring fused steroidal quinolines *in vitro*. **I. Zupkó**, A. Gyovai, Á. Baji, I. Ocsovszki, R. Minorics, É. Frank (Szeged, Hungary)
537. Expanding the inhibitory potency of TIMP-1 against ADAM proteases by the replacement of its C-terminal domain. **M.H. Lee**, A. Tsigkou (Suzhou, P.R. China)
540. Increased progesterone receptor expression in uterine leiomyomas: Correlation with age, number of leiomyomas and clinical symptoms. **A. Tsigkou**, M.H. Lee, F.M. Reis, B. Jiang, C. Tosti, F.-R. Shen, Y.-G. Chen, F. Petraglia (Suzhou; Guangzhou, China; Belo Horizonte, Brazil; Ancona; Siena, Italy)
542. The blood anticoagulant protein S drives oral squamous cell carcinoma tumorigenesis. **G. Abboud-Jarrous**, S. Priya, R. Czerninski, T. Burstyn-Cohen (Jerusalem, Israel)
551. The role of constitutive proteasome and immunoproteasome during acute renal ischemia using human renal tubular epithelial cells. T. Eleftheriadis, **G. Pissas**, G. Antoniadi, V. Liakopoulos, I. Stefanidis (Larissa, Greece)
558. Anti-inflammatory and analgesic effects of bergamot essential oil. G.E. Lombardo, C. Mannucci, S. Cirimi, N. Ferlazzo, S. Pergolizzi, G. Calapai, **M. Navarra** (Messina, Italy)
559. Growth inhibition of HepG2 cells by *Citrus bergamia* juice: Focusing on the molecular mechanisms. N. Ferlazzo, S. Cirimi, G.E. Lombardo, G. Calapai, **M. Navarra** (Messina, Italy)
560. The role of TROP-2 in the proliferation, survival and clonogenicity of breast cancer cells. **T. Nehybová**, P. Beneš, L. Knopfová, J. Remšík, R. Fedr, K. Souček, J. Šmarda (Brno, Czech Republic)